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pathophysiological disease. This stigma is amplified in the context of pregnancy and perpetuates the false,
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Instead of receiving support, education, and encouragement, pregnant women with opioid use disorders are
faced with stigma, judgment, shame, and guilt. These negative interactions ultimately serve as barriers that
interfere with the ability for early attachment bond development, a monumentally important piece of
newborn development and the most significant contributor to healthy attachment development. These
avoidable, institutionally created barriers propagate both short- and long-term risk factors for the mother and
infant, both independently and as a dyad.
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evidence-informed practice model for healthcare providers working with pregnant and postpartum women
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and attachment theory, which will serve as the framework for the PARTNER model, an attachment-based
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ABSTRACT	
	
	 There	are	an	estimated	2.5	million	people	in	the	United	States	of	America	suffering	from	opioid	use	disorders.	Of	the	2.5	million	Americans	impacted	by	opioid	use	disorders,	over	half	are	women.	One	of	the	most	challenging	aspects	of	opioid	use	disorders	occurs	in	the	context	of	pregnancy.	Discourse	surrounding	the	topic	of	addiction	often	identifies	the	root	 cause	 of	 addiction	 as	 a	moral	 failing,	 rather	 than	 a	 pathophysiological	 disease.	 This	stigma	 is	amplified	 in	 the	context	of	pregnancy	and	perpetuates	 the	 false,	discriminatory	notion	that	pregnant	women	with	opioid	use	disorders	are	knowingly	“harming”	their	babies	without	regard.		 Instead	of	receiving	support,	education,	and	encouragement,	pregnant	women	with	opioid	 use	 disorders	 are	 faced	 with	 stigma,	 judgment,	 shame,	 and	 guilt.	 These	 negative	interactions	ultimately	serve	as	barriers	that	interfere	with	the	ability	for	early	attachment	bond	development,	a	monumentally	important	piece	of	newborn	development	and	the	most	significant	contributor	to	healthy	attachment	development.	These	avoidable,	institutionally	created	barriers	propagate	both	short-	and	long-term	risk	factors	for	the	mother	and	infant,	both	independently	and	as	a	dyad.		 This	dissertation	will	systematically	explore	several	aspects	of	perinatal	opioid	use	disorders	to	develop	an	evidence-informed	practice	model	for	healthcare	providers	working	with	pregnant	and	postpartum	women	with	opioid	use	disorders.	This	dissertation	will	also	explore	the	intersection	of	perinatal	opioid	use	disorders	and	attachment	theory,	which	will	serve	as	the	framework	for	the	PARTNER	model,	an	attachment-based	practice	model	for	providers	working	with	mothers	 and	 infants	 impacted	by	perinatal	 opioid	use	disorders.		Composite	 case	 vignettes,	 informed	 by	 clinical	 experience	 and	 empirical	 literature,	 are	integrated	throughout	this	dissertation	to	illuminate	and	connect	the	critical	concepts	that	set	the	foundation	for	the	PARTNER	model.		
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CHAPTER	I:	STATEMENT	OF	THE	PROBLEM	
THE	PERINATAL	OPIOID	EPIDEMIC	
INTRODUCTION,	BACKGROUND,	AND	SIGNIFICANCE	
There	are	an	estimated	2.5	million	people	in	the	United	States	of	America	suffering	from	opioid	use	disorders.	Drug	overdoses	are	the	leading	cause	of	injury	death	in	the	United	States.	According	to	the	Centers	for	Disease	Control	and	Prevention,	an	average	of	115	people	die	from	an	opioid	overdose	on	a	daily	basis	(Centers	for	Disease	Control	and	Prevention,	2018).	Of	the	2.5	million	Americans	impacted	by	opioid	use	disorders,	over	half	are	women.	Furthermore,	women	are	statistically	at	higher	risk	for	experiencing	the	biopsychosocial	risk	factors	that	contribute	to	opioid	dependency	and	addiction	(Ait-Daoud,	Blevins,	Khanna,	Sharma,	&	Holstege,	2017).	Over	the	past	20	years,	incidence	of	opioid	overdose	amongst	women	has	increased	by	400%,	in	comparison	to	an	increase	of	265%	amongst	their	male	counterparts	(Centers	for	Disease	Control	and	Prevention,	2018).		
One	of	the	most	challenging	aspects	of	opioid	use	disorders	occurs	in	the	context	of	pregnancy.	In	2012,	a	baby	with	intrauterine	opioid	exposure	was	born	every	25	minutes.	This	adds	up	to	an	estimated	21,732	babies	in	one	year	(Patrick,	Davis,	Lehman,	&	Cooper,	2015).	This	number	increased	fivefold	between	2000	and	2012	and	the	rates	have	continued	to	rise.	More	than	50	percent	of	babies	born	to	women	who	are	opioid	dependent	are	diagnosed	with	and	treated	for	neonatal	abstinence	syndrome	(NAS),	a	temporary	postnatal	syndrome	characterized	by	chemical	dependency	and	withdrawal	symptoms	in	infants	with	intrauterine	exposure	to	certain	substances,	including	opiates	
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(Galanter,	Kleber,	&	Brady,	2015;	Gomella,	Cunningham,	&	Eyal,	2013;	Sanlorenzo,	Stark,	&	Patrick,	2018).		
The	statistical	prevalence	of	perinatal	opioid	use	disorders	and	NAS	is	certainly	staggering	and	deserving	of	societal	attention.	However,	the	discourse	surrounding	these	sensitive	health	issues	is	less	focused	on	finding	a	solution	and	more	interested	in	the	shock	value	of	“addicted	pregnant	women”	and	their	“addicted	babies,”	a	paradigm	that	only	perpetuates	stigma	and	contributes	to	the	problem	itself.	Decades	of	research	has	consistently	identified	stigma	as	a	significant,	problematic	component	of	the	rhetoric	of	opioid	use	disorders,	and	addiction	in	general	(Cleveland	&	Gill,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland,	Bonugli,	&	McGlothen,	2016;	Dimirci,	Bogen,	&	Klionsky,	2015,	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks,	Clark,	&	Weinreb,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).	
Discourse	surrounding	the	topic	of	addiction	often	identifies	the	root	cause	of	addiction	as	a	moral	failing,	rather	than	a	pathophysiological	disease	(Ahern,	Stuber,	&	Galea,	2006;	Corrigan,	2004;	Fraser,	Barnes,	Biggs,	&	Kain,	2017;	Goffman,	1963;	Kelly,	Saitz,	&	Wakeman,	2016;	Lloyd,	2013;	Major	&	O’Brien,	2005,	Racine,	Sattler,	&	Escande,	2017).	This	stigma	is	amplified	in	the	context	of	pregnancy	and	perpetuates	the	false,	discriminatory	notion	that	pregnant	women	with	opioid	use	disorders	are	knowingly	“harming”	their	babies	without	regard.	Sensationalist	language	further	compounds	this	stigma.	Babies	diagnosed	with	NAS	are	frequently	referred	to	as	“addicted	babies”	within	mainstream	media.	In	reality,	babies	diagnosed	with	NAS	are	not	“addicted”	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Holbrook,	
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2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).		
These	infants	experience	a	physical	dependence	to	the	opiate	and	are	treated	immediately	upon	diagnosis	within	an	appropriate	hospital	setting,	as	described	by	the	National	Library	of	Medicine.	However,	suggesting	that	the	infant	is	“addicted”	implies	behavioral	aspects	of	addiction	disorders	that	infants	simply	cannot	have	developed	in	the	first	few	weeks	of	life	(Galanter	et	al.,	2015).	NAS	is	a	treatable,	temporary	syndrome	(Galanter	et	al.,	2015;	Gomella	et	al.,	2013;	Sanlorenzo	et	al.,	2018).	There	is	a	colossal	stigma	attached	to	giving	birth	to	an	infant	with	NAS	despite	this	scientific,	evidence-based	information.	Ultimately,	those	who	most	suffer	from	this	social	stigma	are	the	mother	and	infant	themselves.	Stigma	is	barrier	to	the	development	of	early	attachment	bonding,	an	vital	aspect	of	early	childhood	development	that	impacts	how	relationships	are	formed	across	the	lifespan	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Stengel,	2014;	Stone,	2015;	Thigpen	&	Melton,	2014).		
The	problematic	terminology	described	above	may	seem	like	a	simple	difference	in	semantics	and	undeserving	of	reevaluation.	This	misconception,	however,	vastly	undermines	the	power	and	influence	of	language	choice,	perception,	and	social	stigma	(Goodyear-Smith	&	Buetow,	2001).	Empirical	research	has	revealed	that	women	with	perinatal	opioid	use	disorders	feel	judged,	stigmatized,	embarrassed,	and	anxious	when	visiting	their	babies	at	the	hospital.	Common	triggers	include	shaming	verbal	and	nonverbal	language	of	healthcare	staff,	subjective	NAS	scoring,	and	the	exclusion	of	the	mother	from	participating	in	the	treatment	plan	for	both	herself	and	for	her	baby.	Instead	
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of	receiving	support,	education,	and	encouragement,	they	are	faced	with	judgment,	coldness,	and	indifference	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).	
As	a	result,	these	mothers	often	avoid	prenatal	care,	communication	with	healthcare	providers,	and	visitation	in	order	to	circumvent	judgment	and	stigmatization.	This	decreases	access	to	medical	care,	treatment,	and	the	ability	to	bond	with	their	babies,	and	unfortunately	can	serve	to	affirm	the	negative	perceptions	of	some	healthcare	providers.	These	negative	consequences	also	interfere	with	the	ability	for	early	attachment	bond	development,	a	monumentally	important	piece	of	newborn	development	and	the	most	significant	contributor	to	healthy	attachment	development.	Early	attachment	bonding	creates	a	pathway	for	the	way	in	which	individuals	engage	in	human	relationships	across	the	lifespan.	These	avoidable,	institutionally	created	barriers	propagate	both	short-	and	long-term	risk	factors	for	the	mother	and	infant,	both	independently	and	as	a	dyad	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	et	al.,	2000;	Thigpen	&	Melton,	2014).		
Healthcare	providers	across	the	country	are	unknowingly	doing	harm	to	both	the	mother	and	the	baby	by	creating	barriers	to	the	development	of	attachment	instead	of	fostering	connections.	There	is	an	extraordinarily	strong	relationship	between	traumatic	childhood	experiences	(physical,	sexual,	and	emotional	abuse	and/or	neglect)	and	
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substance	use	disorders.	With	this	information,	it	becomes	abundantly	clear	that	mothers	in	this	position	are	already	predisposed	to	barriers	to	healthy	attachment	development	(Felitti	et	al.,	1998;	Galanter	et	al.,	2015;	Khoury,	Tang,	Bradley,	Cubells,	&	Ressler,	2010;	Torchalla,	Linden,	Aube,	Strehlau,	Neilson,	&	Krausz,	2014;	Wilson,	2015).	By	diminishing	the	opportunity	to	provide	education	and	foster	healthy	attachments	between	these	mothers	and	their	infants,	providers	are	simultaneously,	and	drastically,	increasing	risk	of	harm	and	perpetuating	this	cycle.	Fortunately,	this	problem	is	both	changeable	and	preventable	with	utilization	of	evidence-based	practices	applied	to	this	specific	population.		
The	literature	that	exists	has	identified	and	described	these	barriers	to	care,	and	simultaneously	provides	recommendations	for	perinatal	opioid	use	disorders	and	NAS	treatment,	many	of	which	require	maternal	engagement	and	participation.	For	example,	new	research	is	exploring	an	alternative	treatment	approach	for	NAS	that	involves	consistent	caregiver	involvement.	The	literature	addresses	the	influence	of	stigma	and	importance	of	empathy	within	the	context	of	this	population.	However,	it	is	elementary	in	depth	and	undervalued	at	best.	The	information	that	exists	is	simply	not	comprehensive	enough	to	bridge	the	gap	between	theory	and	action.	An	actual	practice	model	that	provides	evidence-based	guidance	on	the	actual	delivery	of	services	to	improve	outcomes	does	not	exist	and	is	greatly	needed.	The	outcome	of	this	dissertation	is	the	PARTNER	model,	an	attachment-based	practice	model	that	fills	this	crucial	gap	in	the	literature.			
PRACTICE	MODEL	AND	CASE	STUDY	RESEARCH	APPROACH	This	dissertation	will	systematically	explore	several	aspects	of	perinatal	opioid	use	disorders	to	develop	an	evidence-informed	practice	model	for	healthcare	providers	
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working	with	pregnant	and	postpartum	women	with	opioid	use	disorders.	This	dissertation	will	also	explore	the	intersection	of	perinatal	opioid	use	disorders	and	attachment	theory,	which	will	serve	as	the	framework	for	the	PARTNER	model.			 The	literature	review	is	comprised	of	three	sections	that	provide	the	foundational	context	for	this	model.	The	first	section	of	the	literature	review	provides	an	examination	of	the	social	history	of	opioids	in	the	United	States	of	America	to	gain	a	stronger,	more	defined	understanding	of	the	etiology	and	stigma	of	opioid	use	disorders.	The	second	section	investigates	the	pathophysiology	of	opioid	use	disorders,	focusing	in	on	neurobiological,	biopsychosocial,	and	treatment	facets.	This	information	is	crucial,	as	it	provides	the	fundamental	context	required	to	truly	appreciate	the	unique,	extraordinarily	arduous	facets	of	perinatal	opioid	use	disorder	and	neonatal	abstinence	syndrome.	The	final	section	of	the	literature	review	examines	the	pathophysiology	of	perinatal	opioid	use	disorders	and	neonatal	abstinence	syndrome	and	discusses	how	the	insurmountable	influence	of	stigma	drastically	impacts	this	already	vulnerable	population.			 The	evidence	uncovered	in	the	literature	review	clearly	reveals	that	the	stigmatizing	discourse	and	misinformation	surrounding	perinatal	opioid	use	disorders	serves	as	a	significant	barrier	to	early	attachment	development,	negatively	impacting	one	of	the	most	fundamentally	vital	aspects	of	life.	The	literature	also	reveals	a	substantial	need	for	a	practice	model	that	serves	as	guidance	for	providers	toward	fostering	healthy	early	attachment	development	rather	than	inhibiting	it.	Rooted	in	attachment	theory,	the	PARTNER	model	aims	to	foster	healthy	partnerships	between	the	mother	and	baby,	as	well	as	the	mother	and	provider.		
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Composite	case	vignettes,	informed	by	clinical	experience	and	empirical	literature,	are	integrated	throughout	this	dissertation.	These	case	vignettes	tell	the	story	of	Kiana,	a	23-year-old	black,	heterosexual,	cisgender	woman	with	a	perinatal	opioid	use	disorder.	Pertinent	elements	of	Kiana’s	history	are	integrated	throughout	the	literature	review,	illuminating	and	connecting	her	story	to	the	concepts	that	set	the	foundation	for	the	PARTNER	model,	and,	Kiana’s	story	continues	after	the	introduction	of	the	PARTNER	model.	The	story	of	Kiana’s	journey	through	pregnancy	and	the	birth	of	her	baby,	William,	brings	life	and	connection	to	each	element	of	the	PARTNER	model.		
The	PARTNER	model	has	been	specifically	designed	with	patients	like	Kiana	and	William	in	mind,	whose	story	is	similar	to	many	of	the	women	and	babies	impacted	by	perinatal	opioid	addiction.	Identifying	areas	of	antiquation	and	integrating	strengths-based	interventions	emphasizes	the	importance	of	promoting	attachment	between	a	mother	and	her	infant,	provides	a	person-centered	framework	from	which	to	work,	and	fosters	insight	into	and	mitigation	of	socially-constructed	barriers	that	deepen	the	divide	between	“us”	and	“them.”		
OPERATIONAL	DEFINITIONS	OF	TERMS	
	 The	terms	and	concepts	used	throughout	this	dissertation	are	informed	by	and	derived	from	definitions	from	the	peer-reviewed	literature.	Key	terms	and	concepts	referenced	in	the	literature	review	are	operationally	defined	below	for	clarity	and	contextual	purposes.	The	operational	definitions	of	new	key	terms	and	concepts	utilized	in	the	PARTNER	model	will	be	integrated	into	their	respective	sections.		
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	 Opioid	refers	to	an	analgesic	substance	intended	to	treat	moderate	to	severe	pain.	The	term	“opioid”	is	an	umbrella	term	for	both	naturally	and	synthetically	produced	opiates.	Opioids	interact	with	the	central	nervous	system	to	create	a	sense	of	euphoria	and	immense	dopamine	rush	that	the	brain	cannot	recreate	on	its	own,	thus	contributing	to	its	appeal	and	likelihood	for	misuse,	abuse,	dependency,	and	addiction	(Centers	for	Disease	Control	and	Prevention,	2018).			 There	are	four	categories	of	opioids:	1)	natural	and	semi-synthetic	opioid	analgesics	(including	morphine,	codeine,	hydrocodone,	and	oxycodone),	2)	heroin	(crude	preparation	of	diamorphine),	3)	methadone	(synthetic	opioid	analgesic),	and	4)	other	synthetic	opioids	(including	fentanyl	and	tramadol)	(Centers	for	Disease	Control	and	Prevention,	2018).		
	 Opioid	misuse	refers	to	the	recreational	and	occasional,	but	limited,	use	of	an	opioid	or	opioids	with	the	potential	for	abuse	or	dependence	(Centers	for	Disease	Control	and	Prevention,	2018).	
	 Opioid	abuse	refers	to	recurrent,	continued	opioid	use	despite	negative	consequences,	including	a	marked	decline	in	interpersonal	relationships,	physical	and/or	mental	health,	financial	stability,	and/or	performance	at	work	(Centers	for	Disease	Control	and	Prevention,	2018).	
	 Opioid	dependence	refers	to	the	neurological,	persistent,	involuntary	craving	for	opioid	exposure	which	results	from	neurochemical	changes	from	consistent	opioid	exposure	and	reward	circuit	activation	(Galanter	et	al.,	2015	&	Wilson,	2015).	
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	 Opioid	addiction	refers	to	behavioral,	cognitive,	and	cyclical	aspects	of	opioid	dependency	characterized	by	repeated	periods	of	preoccupation,	craving,	intoxication,	binging,	and	withdrawal.		(Galanter	et	al.,	2015	&	Wilson,	2015).	
	 Opioid	withdrawal	refers	to	the	physiological	symptoms	that	result	from	opioid	exposure	cessation	including	nausea,	vomiting,	sweating,	chills,	diarrhea,	and	anxiety	(American	Psychiatric	Association,	2013).	
	 Opioid	overdose	refers	to	a	potentially	fatal	outcome	of	excessive	opioid	use	identified	by	three	characteristics:	decreased	level	of	consciousness,	pupil	constriction,	and	respiratory	arrest	(Centers	for	Disease	Control	and	Prevention,	2018).	
	 Opioid	use	disorder	refers	to	the	diagnosis	of	opioid	dependency	and	addiction.	The	most	current	edition	of	the	Diagnostic	and	Statistical	Manual	of	Mental	Disorders	(DSM-5)	asserts	that	diagnosis	involves	“a	problematic	pattern	of	opioid	use	leading	to	clinically	significant	impairment	or	distress,	as	manifested	by	at	least	two	[criteria],	occurring	within	a	12-month	period”	(American	Psychiatric	Association,	2013,	p.	541).		Criteria	for	this	diagnosis	include	persistent	desire	to	use,	unsuccessful	attempts	to	stop	use,	negative	impacts	on	one’s	personal	life,	inability	to	fulfill	obligations,	tolerance	development,	and	withdrawal	(American	Psychiatric	Association,	2013).		
	 Perinatal	Opioid	Use	Disorder	refers	to	the	diagnosis	of	an	opioid	use	disorder	in	the	setting	of	the	prenatal	and	postpartum	periods	of	pregnancy	(Galanter	et	al.,	2015).		
	 Neonatal	Abstinence	Syndrome	refers	to	the	diagnosis	of	observed	opioid	withdrawal	symptoms	in	infants	with	intrauterine	opioid	exposure	(Gomella	et	al.,	2013).		
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	 Stigma	refers	to	a	socially-constructed	set	of	negative	beliefs	based	on	assumptions,	preconceived	notions,	and	generalizations	that	contribute	to	discrimination,	exclusion,	prejudice,	and	rejection	(Goffman,	1963).		
	 Attachment	Theory	refers	to	the	psychoanalytic	approach	to	understanding	the	influence	of	fundamental	early	relationship	development	on	interpersonal	relationships,	emotional	salience,	and	affect	regulation	throughout	the	life	cycle	(Bowlby,	1969).		
	 Attachment	Pattern	refers	to	a	specific	relationship	development	category	defined	by	certain	behavioral	characteristics	(Ainsworth,	Blehar,	Waters,	&	Wall,	1978).	Attachment	patterns	are	developed	in	infancy	and	serve	as	the	foundation	for	how	relationships	are	structured	and	understood	in	adulthood.	Secure	attachment	is	established	from	safe,	nurturing,	and	reliable	caregivers,	and	results	in	a	stable,	balanced	framework	for	relationships	in	adulthood.	Insecure	attachment	is	developed	from	dangerous,	neglectful,	and	unreliable	caregivers,	and	results	in	a	chaotic,	imbalanced	framework	for	relationships	in	adulthood.			
	 Attachment	Bond	refers	to	the	actual,	residual	adaptive	and	maladaptive	bonds	that	result	from	early	childhood	relationship	development	(Bowlby,	1969);	the	“lasting	psychological	connectedness	between	human	beings”	(Bowlby,	1969,	p.	194).	
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CHAPTER	II:	LITERATURE	REVIEW	
PART	I:	THE	SOCIAL	HISTORY	OF	OPIOIDS	IN	THE	UNITED	STATES	OF	AMERICA	
THE	ETIOLOGY	OF	THE	OPIOID	EPIDEMIC		 Today,	there	are	currently	over	2.5	million	people	suffering	from	opioid	dependence	in	the	United	States	with	approximately	47,600	opioid	overdose	deaths	in	2017	(Centers	for	Disease	Control	and	Prevention,	2018).	The	Surgeon	General	named	this	crisis	as	the	opioid	epidemic,	sweeping	the	nation	and	the	world	(U.S.	Department	of	Health	and	Human	Services,	2016).	The	presence	of	opioids	in	America,	though	substantially	increasing	in	acuity	over	the	past	twenty	years,	is	not	a	recently	developed	phenomenon.	Opioids	have	been	used	and	incorporated	into	medical	treatment	for	thousands	of	years	all	over	the	world,	but	fundamentally	caught	the	attention	of	Americans	in	the	early	1900s	after	World	War	I.	Opioids,	specifically	morphine,	were	used	as	a	method	of	pain	relief	for	wounded	veterans.	The	popularity	of	opioids	skyrocketed	and	became	a	common	method	of	treatment	for	just	about	anything,	even	the	common	cold	(Heyman,	2015).	It	was	not	until	the	1920s	when	the	government	discovered	the	powerful	addictive	nature	of	opioids.	In	response	to	this	national	problem	and	to	mitigate	this	issue,	Congress	passed	the	Harrison	Narcotics	Tax	Act	in	1914.	This	act	strictly	limited	the	use	of	opium-based	substances	to	licensed	medical	practice.	Later	came	the	Anti-Heroin	Act	of	1924	which	prohibited	the	importation	and	possession	of	opium	(Courtwright,	2001	&	Heyman,	2015).			 Heroin	regained	moderate	popularity	in	the	1950s	as	part	of	pop	culture	but	was	generally	unfamiliar	to	or	feared	by	most	Americans.		It	was	not	until	after	the	Vietnam	War	in	the	1970s	that	the	resurgence	of	heroin	came	back	to	the	United	States	in	full	force	(Courtwright,	2001	&	Heyman,	2015).	At	this	point	in	time,	the	marked	increase	in	opioid	
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overdoses	led	to	President	Richard	Nixon	deeming	heroin	the	“public	enemy	number	one”	(1971).	It	was	at	that	time	in	July	1973	that	the	Drug	Enforcement	Agency	was	created	(Courtwright,	2001	&	Heyman,	2015).			 Attitudes	toward	opiates	shifted	significantly	in	the	1980s,	reflected	in	an	article	published	in	the	New	England	Journal	of	Medicine	in	January	1980	by	Dr.	Hershel	Jick	and	his	graduate	assistant,	Jane	Porter.	In	this	article,	Jick	and	Porter	attempted	to	refute	the	risk	of	dependence	by	explicitly	stating	that	addiction	to	opioids	is	“rare	in	medical	patients	with	no	history	of	addiction”	(Porter	&	Jick,	1980,	p.	123).	The	authors’	motivation	in	publishing	this	information	remains	unclear,	but	the	subsequent	sharp	increase	in	opiate	prescriptions,	dependency,	and	overdose	over	the	following	three	decades	is	irrefutable	(Centers	for	Disease	Control	and	Prevention,	2018	&	Haney,	2017).		 In	the	1990s,	the	extensive	media	coverage	of	cocaine	use	became	prevalent,	ostensibly	overshadowing	the	opioid	dependence	problem.	The	Centers	for	Disease	Control	and	Prevention	(2018)	has	identified	the	1990s	as	the	first	of	three	overdose	waves	in	the	United	States.	This	wave	was	represented	by	a	steep	rise	in	prescription	opioid	overdose	deaths.	Prescriptions	for	opioids	were	provided	to	patients	with	seemingly	no	limitations,	resulting	in	huge	profits	for	pharmaceutical	companies.	When	the	Joint	Commission	on	Accreditation	of	Healthcare	Organizations	integrated	pain	management	into	vital	sign	checks	in	the	early	2000s,	prescriptions	and	abuse	increased	at	an	astonishing	rate.	Based	on	the	prescription	and	healthcare	management	regulations	in	effect	at	that	time,	opioids	became	more	accessible	than	ever	with	little	to	no	concern	for	dependency.	This	cause	and	effect	ostensibly	exacerbated	the	addiction	problem	itself	(U.S.	Department	of	Health	and	Human	Services,	2016).	
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	 By	the	end	of	2010,	these	remarkable	changes	in	opioid	access	and	abuse	came	to	the	forefront	of	the	medical	community.	The	Centers	for	Disease	Control	and	Prevention	(2018)	marked	2010	and	2013	as	the	second	and	third	overdose	waves,	signified	by	a	marked	rise	in	heroin	overdose	deaths	and	synthetic	opioid	overdose	deaths,	respectively.	Since	this	time,	the	federal	government	has	implemented	prescription	drug	monitoring	programs,	as	well	as	stricter	guidelines	and	legal	consequences	for	inappropriate	and/or	excessive	prescribing.	Training	and	education	on	naloxone,	an	emergency	treatment	that	counteracts	opioid	overdose	more	commonly	known	by	the	brand	name	NARCAN,	has	been	widely	expanded	as	well.	Efforts	to	reduce	access	and	treat	dependency	have	vastly	increased,	but	statistical	evidence	strongly	indicates	that	something	is	not	working	(Centers	for	Disease	Control	and	Prevention,	2018).	
	 It	was	not	until	June	2017	that	the	New	England	Journal	of	Medicine	publicly	addressed	the	illegitimacy	and	irresponsibility	of	that	1980	article,	now	commonly	referred	to	simply	as	“Porter	and	Jick.”	In	its	response,	committee	members	of	the	Journal	explicitly	recognized	the	original	content	as	empirically	unsupported	and	a	contributor	to	the	current	opioid	epidemic,	as	it	minimized	the	risk	and	severity	of	addiction	related	to	opiates.	In	addition,	the	Journal	cited	lawsuits	against	pharmaceutical	companies	that	also	misrepresented	the	risk	of	dependence	to	doctors	and	patients	(Leung,	Macdonald,	Stanbrook,	Dhalla,	&	Juurlink,	2017).	Shortly	after	the	publication	of	this	2017	letter,	Dr.	Jick	was	quoted	in	an	interview	saying	the	New	England	Journal	of	Medicine	has	“published	nearly	400	papers	on	drug	safety,	but	never	before	have	we	had	one	that	got	into	such	a	bizarre	and	unhealthy	situation”	(Haney,	2017,	p.	1).	Jick	admitted	“if	I	knew	then	what	I	know	now,	I	would	have	never	published	it”	(Haney,	2017,	p.	1).		
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	 In	2016,	a	year	prior	to	this	response,	the	first	U.S.	Surgeon	General	report	on	addiction	was	published.	In	the	preface,	Dr.	Vivek	Murthy,	the	U.S.	Surgeon	General	at	the	time,	acknowledged	the	need	for	not	only	addiction	treatment	reform,	but	a	reform	of	the	discourse	surrounding	addiction	as	well.	Dr.	Murthy	stipulates	that	the	way	in	which	society	approaches	addiction	conveys	a	false,	stigmatizing	message	that	addiction	is	a	moral	failing	rather	than	a	chronic	illness.	In	this	report,	Dr.	Murthy	stated:	We	also	need	a	cultural	shift	in	how	we	think	about	addiction.	For	far	too	long,	too	many	in	our	country	have	viewed	addiction	as	a	moral	failing.	This	unfortunate	stigma	has	created	an	added	burden	of	shame	that	has	made	people	with	substance	use	disorders	less	likely	to	come	forward	and	seek	help.	It	has	also	made	it	more	challenging	to	marshal	the	necessary	investments	in	prevention	and	treatment.	We	must	help	everyone	see	that	addiction	is	not	a	character	flaw	–	it	is	a	chronic	illness	that	we	must	approach	with	the	same	skill	and	compassion	with	which	we	approach	heart	disease,	diabetes,	and	cancer.	(p.	v)	This	stigma	imposes	shame	and	creates	barriers	to	treatment,	which	only	works	toward	perpetuating	the	opioid	epidemic	rather	than	ending	it	(U.S.	Department	of	Health	and	Human	Services,	2016).		
	 CASE	STUDY	VIGNETTE	
At	age	20,	Kiana	was	involved	in	a	motor	vehicle	accident.	She	was	seen	and	
evaluated	in	the	emergency	department	of	a	local	hospital,	presenting	with	complaints	
of	neck	pain	and	a	headache.	Kiana	was	given	a	30-day	prescription	for	Percocet	
without	any	education	on	risk	of	dependency.	Kiana	did	not	know	how	to	evaluate	and	
treat	her	own	pain	appropriately	at	home	(i.e.	take	an	over-the-counter	analgesic	for	
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lower/moderate	pain	relief),	and	Kiana	assumed	that	because	she	was	given	this	
prescription	by	a	physician,	it	was	safe	to	finish	the	prescription	to	the	end	and	take	
them	every	day.	She	thought	she	was	doing	what	she	was	supposed	to	do.	
	
THE	STIGMA	OF	OPIOID	DEPENDENCY	AND	ADDICTION	Despite	historical	implications,	scientific	evidence	that	distinguishes	an	opioid	use	disorder	as	a	pathology-driven	disease,	and	empirically	identified	risk	factors	associated	with	opioid	use	disorders,	the	stigma	surrounding	opioid	dependency	and	addiction	is	palpable.		The	concept	of	social	stigma	was	first	explored	and	defined	by	sociologist,	Erving	Goffman.	Goffman	identified	stigma	as	a	phenomenon	involving	perceptual	classification	of	people	as	either	normal	or	undesirable	based	on	societally-constructed	beliefs.	Goffman	also	identified	three	groups	of	people	related	to	a	stigma:	1) the	stigmatized,	characterized	by	individuals	or	groups	who	are	associated	with	and	impacted	by	the	stigma,	2) the	normals,	characterized	by	individuals	or	groups	who	are	not	associated	with	nor	impacted	by	the	stigma,	and	3) the	wise,	characterized	by	individuals	or	groups	who	are	not	associated	with	nor	impacted	by	the	stigma,	but	are	fundamentally	aware	of	the	stigma	and	the	way	in	which	it	impacts	the	stigmatized	(Goffman,	1963).		Empirical	research	has	supported	Goffman’s	theory,	with	the	identification	of	two	subgroups	that	exist	within	the	wise:		
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1) the	active	wise,	characterized	by	individuals	or	groups	who	work	toward	and	advocate	for	the	deconstruction	of	a	stigma,	and	2) the	passive	wise,	characterized	by	individuals	or	groups	who	take	a	more	submissive,	indifferent	stance	(Smith,	2012).			 Stigma	has	several	detrimental	consequences	on	the	stigmatized	individuals	and	groups	themselves,	including	direct	effects	on	self-esteem	and	mental	health	and	willingness	to	seek	out	healthcare	and	treatment,	as	well	as	other	harm	reduction	modalities.	The	false,	unsubstantiated	attributes	of	the	stigma	are	often	internalized	as	reality	for	the	stigmatized,	resulting	in	a	decreased	sense	of	self-worth.	Stigma	generates	a	destructive	sense	of	external	condemnation	and	fear	of	poor	quality	of	care,	legal	ramifications,	and	judgment	from	healthcare	providers.		This	is	a	significant	issue	within	the	societal	context	of	addiction,	as	these	associated	schemas	and	rhetoric	further	marginalize	and	shame	an	already	at-risk	population.	Opioid	dependency	and	addiction	is	often	considered	a	moral	failing	with	full	responsibility	placed	upon	the	person	suffering.	This	stigma	is	particularly	damaging,	as	it	directly	attacks	the	integrity,	dignity,	and	value	of	the	person	as	a	human	being	(Ahern	et	al.,	2007;	Earnshaw,	Smith,	&	Copenhaver,	2013;	Lloyd,	2013;	Racine	et	al.,	2017).	Stigma	can	serve	as	a	profound,	biopolitical,	institutionally-created	barrier	and	deterrent	to	healthcare	and	treatment	(Ahern,	2006;	Corrigan,	2004;	Fraser	et	al.,	2017;	Goffman,	1963;	Kelly	et	al.,	2016;	Lloyd,	2013;	Major	&	O’Brien,	2005;	Racine	et	al.,	2017;	Woo	et	al.,	2017).	
CASE	STUDY	VIGNETTE	
Kiana	continued	to	take	the	Percocet	prescription	every	day	and,	as	she	got	
closer	to	the	30-day	mark,	she	noticed	the	bottle	would	be	finished	within	a	just	few	
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days.	Kiana	went	to	her	pharmacy	to	request	a	refill	but	was	told	there	were	no	refills	
available	and	that	she	needed	another	prescription.	Kiana	returned	to	the	same	
emergency	department	to	ask	for	another	prescription,	as	instructed.	Shortly	after	
being	evaluated,	she	overheard	some	staff	members	talking	about	“the	drug	seeker	in	
bed	10.”	She	looked	at	her	wristband	and	noticed	that	she	was	in	bed	10.	They	were	
talking	about	her.		
Rather	than	assessing	for	opioid	dependency	or	offering	psychoeducation,	a	
physician	provided	her	with	another	prescription	and	told	her	“this	is	the	last	one.”	
Kiana	took	the	prescription,	feeling	confused,	embarrassed,	and	ashamed.	She	said	to	
herself	“well,	I’m	not	going	back	there.”		
A	few	days	later,	Kiana	told	her	best	friend,	Ann	Marie,	about	what	happened.	
Ann	Marie	responded	in	disbelief.	“What?	That’s	crazy!	A	drug	seeker?	They’re	the	ones	
that	gave	it	to	you	in	the	first	place!	You’re	no	dope	fiend.	Have	you	seen	those	
people?”	Kiana	thought	to	herself,	“Ann	Marie	is	right,	it’s	not	like	I’m	one	of	them.”	
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PART	II:	THE	PATHOPHYSIOLOGY	OF	OPIOID	DEPENDENCY	AND	ADDICTION	
NEUROBIOLOGICAL	INTERACTIONS	OF	OPIOIDS	AND	THE	BRAIN		 The	perception	of	addiction	as	a	moral	failing	often	overshadows	the	pathophysiology	of	addiction.	To	understand	the	dangerous	allure	of	opioids,	the	first	place	to	investigate	is	the	brain.	The	brain	is	run	by	neurotransmitters,	chemical	molecules	that	send	messages	all	throughout	the	body.	Dopamine,	a	neurotransmitter	naturally	produced	within	the	brain,	instinctively	regulates	the	brain’s	reward-motivation	system	and	guides	motivational	salience.	Motivational	salience	is	a	cognitive	process	that	influences	the	way	in	which	potential	actions	are	evaluated,	and,	therefore,	how	the	individual	behaves	in	response	to	these	evaluations.	Cortisol,	another	naturally-produced	neurotransmitter,	is	responsible	for	regulating	stress.	No	two	brains	are	exactly	alike;	there	are	several	genetic	and	learned	factors	that	contribute	to	the	amount	of	dopamine	and	cortisol	receptors	exist	in	the	brain	(Applegate	&	Shapiro,	2005;	Evans	&	Cahill,	2016;	Maguire,	2013;	Walter	et	al.,	2015;	Wilson,	2015).			 Dopamine	and	cortisol	levels	are	significantly	impacted	by	exposure	to	opioids.	Almost	immediately	after	being	consumed,	opioids	are	absorbed	in	the	bloodstream,	making	their	way	to	the	brain	and	attach	themselves	to	receptors.	They	flood	the	limbic	system	value	circuit	with	dopamine,	and	cortisol	production	is	reduced.	This	rush	of	increased	dopamine	and	decreased	cortisol	produces	a	sensation	of	physical	and	mental	euphoria	(Bisaga,	Chernyaev,	&	McLellan,	2018;	Evans	&	Cahill,	2016;	Walter	et	al.,	2015;	Wilson,	2015).			 When	exposed	to	sharp	increases	in	dopamine	generated	by	opioids,	the	brain	identifies,	classifies,	and	retains	these	preceding	actions	and	behaviors	as	high	reward-
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value	and,	ultimately,	high	incentive-value.	The	baseline	dopamine	that	exists	in	the	brain	increases.	Because	the	enormous	amount	of	dopamine	generated	by	opioids	cannot	be	duplicated	by	the	brain	on	its	own,	the	brain	essentially	becomes	trained	to	crave	the	dopamine-manufacturing	substance.	The	brain	becomes	dependent	on	opioid	exposure	to	function	at	baseline	(Applegate	&	Shapiro,	2005;	Evans	&	Cahill,	2016;	Wilson,	2015).			 When	these	dopamine	levels	drop	below	the	new,	increased	baseline	threshold,	the	brain	excretes	increased	cortisol.	This	action	contributes	to	opioid	withdrawal,	characterized	by	symptoms	opposite	of	euphoria.	When	this	occurs,	the	brain	remembers	that	those	actions	and	behaviors	that	preceded	the	opioid	ingestion	will	result	in	the	craved	dopamine	increase	and	cortisol	decrease.	In	essence,	the	brain	has	been	chemically	trained	to	subconsciously	associate	opioid	use	with	positive	neural	rewards	(Applegate	&	Shapiro,	2005;	Evans	&	Cahill,	2016;	Wilson,	2015).			 From	the	neurobiological	perspective,	dependency	and	addiction	can	be	conceptualized	as	a	reward	deficit	disorder	with	changes	in	impulse	control	and	executive	functioning	(Herron	&	Brennan,	2015).	Opioid	dependency	can	be	characterized	by	the	brain’s	physiological	need	for	opioid	exposure	to	maintain	its	baseline	functioning.	Opioid	addiction	can	be	characterized	by	the	actions	and	behaviors	that	precede	the	opioid	exposure.	These	actions	and	behaviors	are	generally	characterized	by	people,	places,	and	objects	and	serve	as	triggers	for	continued	use,	cravings,	and	relapse.	Once	a	dependency	and	addiction	is	developed,	recovery	can	be	extremely	challenging,	but	it	is	not	impossible.	The	neuroplasticity	of	the	brain	allows	for	these	neural	pathways	and	learned	rewards	are	adaptable	and	reversible	(Evans	&	Cahill,	2016;	Wilson,	2015).		
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CASE	STUDY	VIGNETTE	
It	was	two	months	and	two	prescriptions	since	the	car	accident.	Kiana	was	
again	almost	out	of	Percocet	and	was	trying	to	ration	what	she	had	left.	However,	she	
started	noticing	that	when	she	stopped	taking	the	Percocet	for	a	couple	of	days,	she	
felt	terrible.	She	felt	like	she	had	the	flu	with	symptoms	of	nausea,	vomiting,	insomnia,	
and	night	sweats.	She	thought	to	herself,	“Wow.	I	must	be	really	messed	up	from	that	
car	accident.	I	need	this	stuff.”	What	Kiana	didn’t	realize	is	that	these	were	not	
symptoms	from	the	car	accident.	She	was	experiencing	opioid	withdrawal.		
Kiana	began	to	wonder	how	she	could	get	another	prescription	for	Percocet	
before	running	out	of	what	she	had	left.	She	did	not	want	to	feel	like	this	anymore.	She	
considered	going	to	the	emergency	department,	but	immediately	thought	back	to	the	
terrible	way	staff	made	her	feel.	Kiana	started	to	subtly	ask	around	to	see	if	anyone	she	
knew	had	Percocet	she	could	buy.	Shortly	after	her	search	began,	she	discovered	that	a	
friend	of	a	friend,	Walter,	was	selling	Percocet.	However,	the	pills	came	with	a	steep	
price	tag.		
Walter	told	Kiana	that	he	could	offer	her	heroin	instead,	explaining	that	heroin	
was	“way	cheaper”	and	“way	stronger.”	Kiana	took	a	moment	to	think	it	over,	but	the	
decision	was	made	before	he	could	even	finish	his	sentence.	She	bought	the	heroin	and	
left.	She	told	herself,	“It’s	not	like	I’m	doing	it	all	day,	every	day.	And,	I’m	working	two	
jobs!	This	is	just	temporary	until	I	can	get	this	under	control.	I’m	not	one	of	those	
people.”	
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BIOPSYCHOSOCIAL	RISK	FACTORS		 In	addition	to	neurobiological	implications,	there	are	other	biopsychosocial	factors	and	impacts	on	the	learning	brain	that	impact	the	risk	of	opioid	misuse,	abuse,	dependency,	and	addiction.	Three	of	the	most	empirically	significant	components	include	biological	factors,	adverse	childhood	experiences,	and	psychosocial/environmental	factors	(Ait-Daoud	et	al.,	2017;	Applegate	&	Shapiro,	2005;	Berlin,	Shanahan,	&	Appleyard	Carmody,	2014;	Centers	for	Disease	Control	and	Prevention,	2018;	Covington,	2008;	Galanter	et	al.,	2015;	Goodman,	Milliken,	Theiler,	Nordstrom,	&	Akerman,	2015;	Herron	&	Brennan,	2015;	Khoury	et	al.,	2010;	Maguire,	2013;	Torchalla	et	al.,	2014;	Wilson,	2015).	
BIOLOGICAL	FACTORS		 Biological	influences	on	risk	for	addiction	include	genetics,	gender,	and	neurologic	and	biochemical	factors	(Herron	&	Brennan,	2015;	Maguire,	2013).	As	a	demographic	characteristic,	women	are	experiencing	increases	in	opioid	use	disorders	at	alarmingly	higher	rates	than	men,	and	women	are	more	likely	to	develop	and	suffer	longer	from	opioid	use	disorders.	Since	1999,	the	number	of	opiate	overdose	deaths	among	women	has	increased	by	400%,	compared	to	265%	among	men.	Statistical	evidence	also	indicates	that	women	progress	from	initial	use	to	opioid	use	disorders	much	more	rapidly	than	men	(Centers	for	Disease	Control	and	Prevention,	2018).		 Studies	aimed	to	examine	the	relationship	between	women	and	opioid	use	disorders	is	still	an	underdeveloped	area	of	research.	However,	the	existing	research	does	identify	biological	and	social	factors	that	contribute	to	the	higher	occurrence	of	opioid	use	disorders	in	women.	Researchers	have	identified	some	potential	factors	that	play	a	role	in	this	dynamic,	including	hormones	and	predisposition	to	some	chronic	medical	conditions.	
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Lab	research	has	identified	some	connections	between	sex	hormones	and	likelihood	of	opioid	dependency.	Further	research	shows	women	experience	higher	rates	of	chronic	pain	illnesses	for	which	opiate	pain	medication	is	prescribed	(Ait-Daoud	et	al.,	2017	&	Maguire,	2013).	From	a	social	standpoint,	women	are	at	higher	risk	than	men	for	experiencing	shame	and	stigma	and	barriers	to	financial,	medical,	and	housing	resources	(Ait-Daoud	et	al.,	2017	&	Covington,	2008).	Women	also	experience	substantially	higher	rates	of	experiencing	mental	health	challenges,	internalized	and	externalized	family	role	identity	complexities,	and	physical	and	sexual	abuse	(Covington,	2008).			 According	to	the	National	Institute	on	Drug	Abuse	(2010),	there	is	an	extremely	high	prevalence	of	comorbid	substance	use	disorders	and	another	mental	health	diagnosis.	More	specifically,	research	reveals	that	those	diagnosed	with	a	mood,	anxiety,	trauma-related,	or	stressor-related	disorder	are	at	the	highest	risk	of	developing	a	substance	use	disorder	(National	Institute	on	Drug	Abuse,	2010).	Furthermore,	women	who	experience	postpartum	depression	are	at	added	risk	for	developing	substance	use	and	potential	dependency	(Ait-Daoud	et	al.,	2017).			 There	are	several	challenges	that	exist	within	the	examination	of	substance	use	disorders	and	mental	illness.		While	research	does	indicate	a	significant	relationship	between	mental	health	and	substance	use	disorders,	it	is	sometimes	impossible	to	determine	which	problem	precedes	the	other.	In	some	cases,	drug	use	increases	symptoms	of	preexisting	mental	illnesses	that	may	or	may	not	have	already	been	identified.	The	fact	that	substance	use	can	alter	brain	chemistry	makes	this	distinction	even	harder	to	identify.	In	other	cases,	drug	use	occurs	after	the	mental	health	symptoms	manifest.	It	is	also	difficult	to	generalize	the	extent	to	which	one	impacts	the	other,	as	the	level	and	intensity	
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of	addiction	and	mental	illness	varies	so	greatly	(National	Institute	on	Drug	Abuse,	2010).	Regardless	of	epidemiology,	risk	for	both	substance	use	disorders	and	mental	health	issues	is	increased	by	overlapping	external	determinants,	including	psychosocial	and	environmental	factors	(Galanter	et	al.,	2015;	Herron	&	Brennan,	2015;	Khoury	et	al.,	2010;	Torchalla	et	al.,	2014;	Wilson,	2015).		
CASE	STUDY	VIGNETTE	
Kiana	grew	up	in	Philadelphia,	Pennsylvania	in	a	modest	home	with	her	
mother,	father,	and	two	younger	sisters.	Her	father	worked	as	a	chef	in	a	restaurant	
and	her	mother	stayed	at	home.	Every	so	often,	her	parents	struggled	to	make	ends	
meet,	but	they	were	generally	able	to	get	by.	Kiana’s	family	lived	in	one	of	the	lower-
income	neighborhoods	in	the	city,	but	she	often	thought	to	herself	that	it	could	“always	
be	worse.”	Kiana	viewed	her	household	with	the	same	mentality,	and	from	the	outside	
looking	in,	things	seemed	okay.	However,	Kiana’s	home	life	was	chaotic.		
Kiana’s	father	struggled	with	alcohol	abuse	and	bipolar	disorder.	He	viewed	
asking	for	help	as	a	sign	of	weakness,	so	he	never	received	any	kind	of	counseling	or	
medication	management.	He	often	came	home	from	work	late	at	night	with	the	smell	
of	liquor	on	his	breath.	Her	parents	fought	frequently,	especially	when	alcohol	was	
involved.	Her	father	was	verbally,	and	sometimes	physically	abusive	toward	her,	her	
mother,	and	her	younger	sisters.	Her	parents	divorced	when	she	was	15	and	she	has	
only	seen	her	father	a	handful	of	times	since	then,	but	she	lived	in	fear	of	him	for	as	
long	as	she	could	remember.				
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ADVERSE	CHILDHOOD	EXPERIENCES		 Adverse	childhood	experiences,	also	referred	to	as	ACEs,	are	stressful,	traumatic	events	that	occur	specifically	in	childhood	and	have	been	empirically	linked	to	negative	health	outcomes,	including	addiction.	The	concept	of	ACEs	originates	from	a	longitudinal	study	conducted	by	Kaiser	Permanente	and	the	Centers	for	Disease	Control,	that	examined	the	relationship	between	traumatic,	stressful	childhood	experiences	and	health	outcomes	in	adulthood.		The	ACEs	study	included	a	wide	variety	of	stressful	and/or	traumatic	experiences	such	as	witnessing	and/or	experiencing	verbal	and/or	physical	abuse,	low	self-esteem	and	self-worth,	disruptions	within	the	function	of	the	family	system,	family	history	of	addiction	and/or	mental	illness,	and	lack	of	access	to	basic	needs	including	food,	shelter,	and	safety	(Felitti	et	al.,	1998).		 The	strong	correlation	discovered	between	ACEs	and	health	outcomes	was	extraordinary,	revealing	a	significant	relationship	between	one’s	ACE	score	and	negative	health	outcomes.	As	an	ACE	score	increases,	so	does	one’s	risk	for	physical	illness	and	social	and	emotional	problems.	With	an	ACE	score	of	just	4,	individuals	begin	to	face	significant	challenges,	including	increased	risk	for	and	occurrence	of	physical	illness	(i.e.	heart	disease,	obesity,	cancer,	liver	disease),	mental	illness	(depression,	anxiety,	suicidal	ideation,	alcohol	and	substance	use	disorders),	and	interpersonal	issues	(interpersonal	violence,	intimate	partner	violence,	homelessness,	unemployment).	The	occurrence	of	multiple	ACEs	is	synergistic,	meaning	the	interaction	between	each	ACE	produces	a	greater	combined	effect	than	the	sum	of	each	individual	ACE	effects.	This	study	also	revealed	that	adverse	childhood	experiences	are	incredibly	common.	Approximately	64%	of	the	17,000	surveyed	adults	reported	at	least	one	ACE	occurrence	(Felitti	et	al.,	1998).	Since	that	time,	
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numerous	other	studies	have	been	conducted	amongst	a	variety	of	populations	with	consistent,	significant	results	(Centers	for	Disease	Control	and	Prevention,	2016).		
CASE	STUDY	VIGNETTE	
In	high	school,	Kiana	was	referred	to	the	school	psychologist	due	to	truancy	
issues.	Kiana’s	evaluation	involved	an	extensive	assessment,	including	the	Adverse	
Childhood	Experience	(ACE)	Questionnaire,	which	resulted	in	an	astonishing	score	of	
8/10.	Kiana	was	diagnosed	with	depression	and	posttraumatic	stress	disorder	and	was	
referred	to	a	psychiatrist	and	therapist.	Kiana	was	reluctant	to	follow	through	with	
this	recommendation	but	did	so	anyway	to	appease	her	mother.		
Kiana	saw	a	counselor	for	a	few	months	but	stopped	when	she	graduated	from	
high	school	and	got	a	full-time	job	at	a	local	restaurant.	She	actually	had	started	to	
like	counseling,	but,	when	left	with	the	decision	to	prioritize	herself	or	work	double	
shifts	to	help	support	her	mother	and	two	younger	sisters,	she	chose	the	latter.		
	
PSYCHOSOCIAL/ENVIRONMENTAL	FACTORS		 There	are	empirically	significant	connections	between	addiction	and	trauma	experienced	in	adulthood	as	well.	Psychosocial	factors,	including	interpersonal	and	environmental	influences,	have	a	strong	impact	on	risk	for	addiction.	One	of	the	most	impactful	influences	on	risk	for	addiction	is	psychological	trauma,	referring	to	trauma	that	meets	criteria	for	acute	stress	disorders	(i.e.	posttraumatic	stress	disorder)	and	complex	trauma	(Berlin	et	al.,	2014;	Goodman	et	al.,	2015;	Herron	&	Brennan,	2015;	Khoury	et	al.,	2010;	Maguire,	2013).	Trauma	is	vast	and	all-encompassing;	it	refers	to	the	single-	or	multi-occurrence	of	a	psychologically	distressing	experience,	the	way	in	which	that	
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experience	is	uniquely	and	collectively	processed,	and	the	short-	and	long-term	impact	of	the	experience.	These	traumas	can	include,	but	are	not	limited	to,	physical,	sexual,	and	emotional	abuse	and/or	neglect.	(Khoury	et	al.,	2010).	Over	half	of	women	with	addiction,	who	are	already	predisposed	to	risk	for	addiction	based	on	their	gender	alone,	meet	criteria	for	posttraumatic	stress	disorder	(Goodman	et	al.,	2015).	When	exposed	to	trauma,	the	developing	brain	produces	less	dopamine,	leaving	the	brain	to	seek	out	external	sources	of	dopamine	production	(Applegate	&	Shapiro,	2005).			 Environmental	influences	on	risk	for	addiction	include	internal	and	external	factors	that	contribute	to	stress,	alienation,	and/or	isolation.	Examples	of	external	factors	include	socioeconomic	status,	minority	status,	neighborhood/community	violence,	household	dysfunction,	and	lack	of	access	to	resources.	Communities	with	higher	rates	of	crime,	violence,	and	poverty	are	linked	to	increased	risk	for	substance	experimentation	and	substance	use	disorders	(Galanter	et	al.,	2015;	Herron	&	Brennan,	2015;	Maguire,	2013).	However,	these	statistics	are	not	always	the	rule.	There	are	many	members	of	impoverished,	disenfranchised	communities	who	never	experiment	with	substances	or	develop	an	addiction.	Internal	factors,	such	as	resiliency	and	individual	response	to	external	environmental	stressors,	also	influence	risk	for	addiction	(Maguire,	2013).		
CASE	STUDY	VIGNETTE	
Shortly	after	Kiana	graduated	from	high	school,	she	started	her	new	job	at	a	
restaurant	in	the	nearby	neighborhood.	One	night,	while	walking	home	from	a	late-
night	work	shift,	Kiana	was	raped	at	gunpoint.	Kiana	never	talked	to	anyone	about	
what	had	happened	to	her	that	night.	She	didn’t	even	want	to	think	about	it.	She	just	
wanted	to	pretend	it	never	happened.		
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A	few	weeks	later,	Kiana	discovered	that	she	was	pregnant.	She	hadn’t	been	
sexually	active	with	any	other	partners,	so	she	knew	the	pregnancy	resulted	from	the	
rape.	Kiana	only	ever	disclosed	the	rape	and	pregnancy	to	her	best	friend,	Ann	Marie.	
“I	don’t	want	to	talk	about	it,	I’m	fine”	Kiana	said.	“Just	please	take	me	to	the	nearest	
abortion	clinic	and	don’t	mention	this	to	anyone.”	Over	the	next	few	months,	Ann	Marie	
made	several	offers	to	help	Kiana	file	a	police	report	or	find	a	counselor.	Kiana	always	
declined	and	said	she	was	“completely	fine.”		
	
OPIOID	USE	DISORDER	TREATMENT	APPROACHES		 There	are	many	models	of	and	approaches	to	substance	use	disorder	treatment.	This	section	will	review	the	four	umbrella	modes	of	treatment	that	are	specifically	geared	toward	opiate	addiction.	These	methods	include	detoxification,	twelve-step	recovery,	behavioral	treatment,	and	medication-assisted	treatment.	These	treatment	modalities	can	be	used	independently	of	or	in	conjunction	with	one	another.		
DETOXIFICATION	
	 The	most	common	method	of	treatment	for	opioid	use	disorders	is	detoxification,	which	involves	rapid	cessation	of	use	while	being	monitored	in	a	controlled	medical	setting,	such	as	a	hospital.	Despite	its	widespread	utilization,	detoxification	has	been	shown	to	be	exceptionally	ineffective	and	has	little	to	no	short-	or	long-term	benefits.	This	is	especially	evident	when	detoxification	is	not	immediately	followed	by	another	form	of	treatment.	Most	of	those	who	complete	the	detoxification	process	relapse	shortly	afterward	(Herron	&	Brennan,	2015	&	Galanter	et	al.,	2015).		
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TWELVE-STEP	RECOVERY	
	 Twelve-step	recovery,	founded	in	1935,	involves	structured,	community-based	support	groups	for	people	with	substance	use	disorders.	They	are	intended	to	be	safe,	judgment-free,	and	facilitated	by	group	members	themselves.	There	are	several	groupings	of	twelve-steps	that	address	specific	substances,	like	Narcotics	Anonymous.	They	are	generally	free	of	charge,	aside	from	optional	donations,	and	are	held	in	various	types	of	community	centers.	Group	members	are	entitled	to	a	sponsor,	who	is	typically	a	member	of	the	group	who	has	maintained	sobriety	and	able	to	serve	as	a	mentor	to	newer	group	members.	The	twelve-step	model	functions	as	a	set	of	principles	for	leading	a	moral	life,	while	simultaneously	guides	participants	through	the	journey	of	achieving	and	maintaining	sobriety	(Herron	&	Brennan,	2015	&	Galanter	et	al.,	2015).	Though	twelve-step	groups	are	not	considered	to	be	treatment	and	are	not	recommended	to	be	utilized	as	the	sole	source	of	recovery,	they	have	been	shown	to	be	successful	in	aiding	recovery	(Fiorentine	&	Hillhouse,	2000).		
BEHAVIORAL	TREATMENT	
	 Behavioral	treatment	for	substance	use	disorders	involves	theoretically-rooted,	evidence-based	psychotherapy	and	are	delivered	in	a	combination	of	inpatient,	outpatient,	group	and	individual	settings.	Most	behavioral	treatment	approaches	utilize	Prochaska	and	diClemente’s	model	of	change	as	its	foundation,	which	identifies	five	stages	of	addiction	recovery.	These	five	stages	include:	1) Precontemplation,	which	involves	no	concrete	intention	to	take	action	within	the	foreseeable	future;	
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2) Contemplation,	which	involves	intention	to	take	action	within	the	foreseeable	future	(approximately	six	months	or	less);	3) Preparation,	which	involves	intention	to	take	action	in	the	immediate	future	(approximately	one	month);	4) Action,	which	involves	making	specific,	measurable,	observable	changes	in	behavior;	and	5) Maintenance,	which	involves	actively	working	to	prevent	relapse	(Herron	&	Brennan,	2015).			 The	theoretical	approaches	with	the	strongest	evidentiary	support	include	motivational	interviewing,	cognitive	behavioral	therapy,	relapse	prevention,	and	solution-focused	therapy.	Group	and	family	treatment	approaches	are	also	very	well-supported.	Behavioral	treatment	programs	can	be	especially	beneficial	for	those	who	have	a	comorbid	mental	illness	that	contributes	to	challenges	in	maintaining	sobriety	(Herron	&	Brennan,	2015	&	Lewis,	2014).		
MEDICATION-ASSISTED	TREATMENT	
	 The	DSM-5	identifies	maintenance	therapy,	also	referred	to	as	medication-assisted	treatment,	as	one	specifier	of	the	opioid	use	disorder	diagnosis.	This	additional	specifier	is	used	“if	the	individual	taking	a	prescribed	agonist	medication	such	as	methadone	or	buprenorphine	and	none	of	the	criteria	for	opioid	use	disorder	have	been	met	for	that	class	of	medication	(except	tolerance	to,	or	withdraw	from,	the	agonist)”	(American	Psychiatric	Association,	2013,	p.	541).			 Medication-assisted	treatment	programs	are	evidence-based	and	involve	a	combination	of	medication	and,	in	some	cases,	behavioral	treatment	intervention.	
 36 
Medications	used	for	medication-assisted	treatment	are	either	full	agonists	or	partial	agonists.	Full	agonists	attach	to	receptors	in	the	brain	to	the	fullest	extent	without	a	ceiling	effect.	The	presence	of	full	agonist	molecules	correlates	directly	to	the	neurological	effects.	Partial	agonists	attach	to	receptors	in	the	brain	as	well,	but	at	only	about	50	percent.	Partial	agonists	have	a	ceiling	effect,	meaning	that	once	the	drug	attaches	to	the	receptor	to	its	fullest	extent,	the	addition	of	more	agonist	molecules	has	no	effect	(Bisaga	et	al.,	2018;	Herron	&	Brennan,	2015).			 The	three	medications	used	in	medication-assisted	treatment	programs	for	opioid	use	disorder	management	include:		1) methadone,	a	full	agonist	2) buprenorphine,	a	partial	agonist	3) naltrexone,	an	antagonist.			 These	three	medications	were	not	developed	or	introduced	as	treatment	options	until	the	mid-1960s.	Though	they	are	different	prescriptions,	they	behave	similarly	to	one	another	in	the	opioid	use	disorder	treatment	process.	Methadone,	buprenorphine,	and	naltrexone	interact	with	the	nervous	system	and	can	reduce	pain	but	lack	the	chemical	compound	that	contributes	to	euphoria.	Methadone	and	buprenorphine	are	most	often	dispensed	at	clinics,	where	the	patient	may	also	receive	group	and/or	individual	counseling	to	help	treat	the	behavioral	aspect	of	the	addiction	while	their	physical	dependency	is	addressed	with	the	medication	(Bart,	2012).	Naloxone	(also	known	as	NARCAN)	is	a	short-term	antagonist	that	is	primarily	used	in	the	acute	setting	of	an	overdose	to	reverse	the	effect	of	the	opioid,	rather	than	as	an	ongoing,	maintenance	medication	(Herron	&	Brennan,	2015).		
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CASE	STUDY	VIGNETTE	
Kiana	was	able	to	keep	her	heroin	use	a	secret	until	she	had	her	first	overdose	
shortly	after	she	turned	23	years	old.	Kiana	had	tried	to	stop	using	heroin	cold	turkey	
the	week	before,	managing	to	go	four	days	without	using	until	the	cravings	and	
withdrawal	symptoms	felt	out	of	control.	On	the	verge	of	relapse,	she	called	Walter	
and	bought	double	the	amount	of	heroin	she	was	used	to	taking	in	hopes	of	
immediately	reversing	the	gut-wrenching	withdrawal.		
Kiana	had	seen	the	horror	of	several	friends’	overdoses,	but	in	this	moment,	the	
urge	to	use	seemingly	drowned	out	this	entire	thought	process	as	she	injected	the	
heroin	into	her	arm.	The	cravings	and	withdrawal	were	overwhelming	and	ostensibly	
took	over	her	body.	And	then,	everything	went	dark.		
When	Kiana	woke	up,	she	was	laying	in	the	ground	surrounded	by	paramedics.	
Kiana	felt	disoriented	and	everything	was	blurry,	but	she	immediately	knew	what	
happened.	She	realized	she	had	just	overdosed.	When	the	paramedic	told	her	he	just	
gave	her	NARCAN,	Kiana	started	sobbing	and	apologizing.	The	paramedic	could	tell	
this	was	her	first	overdose	and	he	assured	her	that	she’d	be	able	to	get	help	when	they	
got	her	to	the	hospital.	But,	the	Kiana	heard	nothing	he	said.	The	sound	of	the	
paramedic’s	voice	was	muffled	by	her	deafening	thoughts.	“I’m	one	of	them,	I’m	one	of	
them.”		 	
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PART	III:	THE	PATHOPHYSIOLOGY	OF	PERINATAL	OPIOID	USE	DISORDERS	
PERINATAL	OPIOID	USE	DISORDERS	
	 Paralleling	the	general	population,	there	has	been	a	marked	increase	in	incidence	of	perinatal	opioid	use	disorders.	Although	there	are	no	statistics	available	that	directly	measure	incidence	of	perinatal	opioid	use	disorders	directly,	hospitals	saw	an	increase	in	opioid-exposed	infants	from	1.5	cases	per	1,000	births	in	1999	to	6	cases	per	1,000	births	in	2013	(American	College	of	Obstetrics	and	Gynecology,	2017).	Opioid	use	disorders	become	significantly	more	complicated	during	pregnancy	due	to	several	factors	including	differences	in	treatment	options	and	barriers	to	care,	both	concrete	and	socially-constructed	in	nature.	Perinatal	opioid	use	disorders	have	unique	challenges	and	considerations	in	terms	of	the	prenatal	and	postpartum	periods,	as	well	as	differential	experiences	and	needs	for	the	mother	and	the	baby	(American	College	of	Obstetrics	and	Gynecology,	2017;	Tauger,	2017;	Wendell,	2013).			 Intrauterine	substance	exposure	occurs	when	a	pregnant	woman	has	consumed	a	substance	that	passes	the	placental	wall	and	blood-brain	barrier	of	the	fetus.	The	amount	of	fetal	exposure	and	incidence	of	withdrawal	is	dependent	on	the	amount	and	frequency	of	substance	use,	as	well	as	the	physiological	makeup	of	the	placenta	and	fetus	itself	(Galanter	et	al.,	2015;	Gomella	et	al.,	2013;	Hudak	&	Tan,	2012).	As	previously	mentioned,	evidence-based	research	indicates	that	opioid	dependence	can	be	successfully	treated	with	abstinence-oriented	treatment	and	medication-assisted	treatment	programs.	For	pregnant	women,	however,	abstinence-oriented	treatment	programs	are	not	medically	recommended	due	to	risk	of	relapse	and	mortality.	Though	acute	opioid	withdrawal	is	uncomfortable	for	adults,	there	are	no	risks	of	fatality.	The	risk	of	fatality	to	the	fetus,	
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however,	is	extremely	high	(American	College	of	Obstetricians	and	Gynecologists,	2017).	These	treatment	limitations	are	also	accompanied	by	barriers.	Access	to	medication-assisted	treatment	can	be	challenging	depending	on	geographical	location,	insurance	coverage,	and	willingness	and	capacity	for	providers	to	treat	addiction	during	pregnancy.	This	is	especially	challenging	for	women	who	seek	out	initiation	of	treatment	during	pregnancy	(American	College	of	Obstetricians	and	Gynecologists,	2017).		 Infants	exposed	to	methadone	or	buprenorphine	are	at	risk	for	the	same	symptoms,	but	at	a	decreased	level	(Behnke,	M.	&	Smith,	V.,	2013;	Shaefer,	Peters,	&	Miller,	2015).	Research	has	consistently	shown	lower	severity	of	symptoms	and	length	of	treatment	for	NAS	among	babies	with	intrauterine	buprenorphine	exposure	in	comparison	to	babies	with	intrauterine	methadone	exposure	(Jones	et	al.,	2005	&	Jones	et	al.,	2008).	Naloxone,	though	safe	to	prescribe	in	general,	is	not	prescribed	to	pregnant	women	due	to	lack	of	evidence	that	supports	safety	to	the	fetus	(Jones	et	al.,	2008).			
CASE	STUDY	VIGNETTE	
After	arriving	at	the	emergency	department,	the	medical	team	told	Kianna	they	
needed	to	complete	a	full	workup	and	run	some	routine	labs,	including	a	urine	drug	
screen,	complete	blood	count	(CBC),	and,	because	Kiana	is	a	female,	a	pregnancy	test.	
Kiana	laid	on	the	stretcher	in	the	room	by	herself	for	a	few	hours,	reflecting	back	on	
the	time	she	was	given	that	very	first	Percocet	prescription	in	this	exact	same	
emergency	room	three	years	ago.		She	told	herself	that	this	is	her	rock	bottom;	this	was	
her	wake-up	call.	She	decided	she	was	going	to	muster	up	the	courage	to	ask	the	
doctor	for	help	when	she	came	back	with	the	test	results.		
 40 
However,	the	conversation	about	getting	treatment	that	she	had	played	out	in	
her	head	came	to	an	abrupt	halt	when	she	was	told	her	pregnancy	test	is	positive.	
Countless	thoughts	and	questions	started	speeding	through	her	mind.	Within	an	
instant,	Kiana	froze	on	one	question	–	what’s	going	to	happen	to	the	baby?	
	
NEONATAL	ABSTINENCE	SYNDROME	(NAS)	
	 Neonatal	abstinence	syndrome	occurs	when	an	infant	with	intrauterine	substance	exposure	is	born	dependent	on	the	substance	exposed	and	starts	to	show	symptoms	of	withdrawal	after	birth.	NAS	can	be	caused	by	many	licit	and	illicit	substances	aside	from	opioids	and	their	agonists,	including	alcohol,	caffeine,	and	SSRIs.	Approximately	60-90%	of	infants	exposed	to	opioids	in	utero	are	diagnosed	with	and	treated	for	NAS	(Galanter	et	al.,	2015	&	Gomella	et	al.,	2013).	The	American	Academy	of	Pediatrics	recommends	that	babies	with	exposure	to	opioids	or	opioid-like	substances	remain	in	the	hospital	for	at	least	five	postpartum	days	to	monitor	for	NAS	(Hudak	&	Tan,	2012).			 The	onset	of	withdrawal	symptoms	can	range	from	immediately	after	birth	to	several	days	after	birth,	hence	the	American	Academy	of	Pediatrics’	recommendation	for	extended	admission	for	monitoring.	Infants	with	suspected	NAS	are	typically	evaluated	using	the	Modified	Finnegan’s	Scoring	System	for	Neonatal	Withdrawal,	a	scoring	system	comprised	of	subjective	and	objective	withdrawal	observations	(Finnegan,	Connaughton,	Kron,	&	Emich,	1975).	The	occurrence	of	three	consecutive	scores	of	seven	or	greater	is	indication	for	treatment	(Gomella	et	al.,	2013;	Hudak	&	Tan,	2012;	Schaefer	et	al.,	2015).	
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PHARMACOLOGICAL	TREATMENT		 	Pharmacological	treatment	for	NAS	involves	administration	of	a	like	drug,	one	that	interacts	with	the	same	receptors	as	the	drug	of	exposure.	For	instance,	infants	with	intrauterine	exposure	to	opiates	are	often	treated	with	morphine,	an	opiate	that	acts	on	the	same	receptors.	In	some	cases,	other	drugs	like	phenobarbital	or	clonidine	are	used	in	conjunction	with	the	like	drug	to	manage	exacerbated	withdrawal	symptoms.	Medication	is	administered	and	titrated	based	on	withdrawal	symptoms	as	indicated	by	the	Modified	Finnegan’s	Scoring	System	for	Neonatal	Withdrawal,	which	involves	both	subjective	and	objective	observations	(Gomella	et	al.,	2013	&	Kraft,	Stover,	&	Davis,	2016).	Infants	treated	for	NAS	have	an	average	hospital	length	of	stay	of	21	days,	whereas	the	average	length	of	stay	for	an	otherwise	healthy	newborn	is	up	to	three	days.	This	extended	length	of	stay	in	the	neonatal	critical	care	setting	is	incredibly	expensive	and	a	drain	on	medical	resources.	National	hospital	expenses	for	NAS	treatment	(adjusted	to	reflect	inflation)	increased	from	$190	million	in	2000	to	$720	million	in	2009	(Patrick	et	al.,	2012).	As	an	effort	to	mitigate	these	rising	healthcare	costs,	new	empirical	research	is	being	generated	to	measure	the	efficacy	of	non-pharmacological	treatment	approaches	in	addition	to	the	preexisting	pharmacological	approaches.		
NONPHARMACOLOGICAL	TREATMENT	Although	analgesics	are	the	current	standard	of	care	for	NAS	treatment,	there	are	also	nonpharmacological	methods	that	can	be	implemented	as	well.	The	most	thoroughly	researched	approaches	include	breastfeeding,	bonding,	swaddling,	and	cuddling,	low-stimulus	environments,	and	increased	family	involvement,	primarily	the	parent(s)	of	the	baby.		Several	empirical	research	studies	suggest	that	incorporating	these	
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nonpharmacological	factors	into	treatment	planning	leads	to	a	remarkable	decrease	in	withdrawal	symptoms,	length	of	hospital	stay,	and	hospital	costs	(Boucher,	2017;	Gomella	et	al.,	2013;	Grossman,	Lipshaw,	Osborn,	&	Berkwitt,	2018;	Holmes	et	al.,	2016;	Howard	et	al.,	2017;	MacMullen,	Dulski,	&	Blobaum,	2014;	Maguire,	2014;	Newman	et	al.	2015;	Patrick	et	al.,	2016;	Pritham,	2013;	Short,	Gannon,	&	Abatemarco,	2016;	Velez	&	Jansson,	2008).		Despite	the	benefits	of	breastfeeding	on	neonatal	abstinence	treatment	outcomes,	breastfeeding	and	co-occurring	opioid	use,	both	prescribed	or	illicit,	is	contraindicated.	However,	there	are	no	known	contraindications	of	breastfeeding	and	co-occurring	methadone	and/or	buprenorphine	use	(American	College	of	Obstetricians	and	Gynecologists,	2017).		
OUTCOMES	FOR	INTRAUTERINE	OPIOID	EXPOSURE		 Infants	with	opioid	exposure	in	pregnancy,	including	methadone	and	buprenorphine,	have	an	overall	strong	prognosis	in	terms	of	physical	and	behavioral	outcomes	in	the	infancy	period.	Intrauterine	opioid	exposure	has	minimal,	if	any,	influence	on	fetal	growth,	congenital	anomalies,	or	neurological	outcomes	(Behnke	et	al.,	2013).	Aside	from	withdrawal,	the	two	short-term	risks	identified	by	the	literature	included	an	increased	risk	for	sudden	infant	death	syndrome	and	strabismus,	a	treatable	misalignment	of	the	eyes.	In	terms	of	neurodevelopment,	infants	with	intrauterine	opioid	exposure	generally	catch	up	to	their	non-exposed	peers	by	one	to	two	years	of	age,	with	the	vast	majority	functioning	within	the	normal	range	of	mental	and	motor	development	by	five	to	six	years	of	age	(Gomella	et	al.,	2013;	Logan,	Brown,	&	Hayes,	2013;	Maguire	et	al.,	2016).				
	 	Infants	with	intrauterine	opioid	exposure,	including	methadone	and	buprenorphine,	also	have	an	overall	strong	prognosis	in	terms	of	physical	and	behavioral	
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outcomes	across	childhood,	adolescence,	and	adulthood.	Intrauterine	opioid	exposure	has	minimal,	if	any,	influence	on	long-term	physical	development,	behavior,	cognitive	and	executive	functioning,	speech	and	language	development,	academic	achievement,	or	predisposition	to	opioid	dependency	and/or	addiction	later	in	life	(Behkne	et	al.,	2013).	Current	research	suggests	that	the	environment	in	which	the	child	grows	up	has	a	more	significant	impact	on	outcomes.	Infants	who	are	raised	in	nurturing,	supportive,	stable	homes	with	access	to	resources	are	more	likely	to	reach	the	positive	neurodevelopmental	outcomes	than	their	counterparts	who	are	raised	in	neglectful,	inconsistent,	and	unstable	home	environments.	Early	infancy	and	childhood	attachment	development	between	infants	and	their	caregivers	decreases	this	risk.	These	social	and	family	protective	factors	also	decrease	risk	for	opioid	use,	dependency,	and	addiction	later	in	life	as	well	(Herranz,	2014;	Logan	et	al.,	2013).	 		
CASE	STUDY	VIGNETTE	
Kiana	has	wanted	to	be	a	mother	for	as	long	as	she	could	remember.	Her	first	
sister	was	born	when	she	was	seven,	and	the	second	was	born	when	she	was	nine.	Her	
earliest	memories	include	being	her	mother’s	“big	sister	helper,”	handing	her	mother	
diapers	and	choosing	which	of	her	favorite	books	she’d	read	to	“her”	baby	before	
bedtime.	She	spent	every	summer	taking	her	sisters	to	the	park	and	the	community	
pool,	always	taking	on	the	role	of	“the	mommy”	when	they’d	play	make-believe.		
The	idea	of	being	“mommy”	came	to	light	again	about	a	year	ago	when	Kiana	
met	her	boyfriend,	Matthew.	They	talked	about	getting	married	and	starting	a	family	
one	day.	They	even	talked	about	their	favorite	baby	names	–	William,	meaning	
“protector,”	for	a	boy	or	Briana,	meaning	“strong,”	for	a	girl.	They	both	knew,	however,	
 44 
that	these	dreams	would	have	to	remain	dreams	until	Kiana	addressed	her	addiction.	
Kiana	knew	what	it	was	like	to	grow	up	in	a	house	filled	with	addiction	and	chaos.	She	
always	dreamed	of	giving	her	children	a	better	life	than	the	one	she	lived	herself.		
	
THE	STIGMA	OF	PERINATAL	OPIOID	USE	DISORDERS		The	stigma	that	exists	toward	opioid	dependency	and	addiction	is	monumentally	amplified	in	the	setting	of	perinatal	opioid	use	disorders.	Empirical	research	consistently	identifies	stigma,	guilt,	and	shame	as	the	biggest	challenge	for	mothers	with	prenatal	substance	use	disorders.	Unfortunately,	there	is	very	limited	research	on	stigma	and	pregnancy	in	terms	of	substance	use	disorders.	The	standing	research	does	indicate	that	stigma	exists	amongst	mothers	who	give	birth	to	an	infant	with	NAS	due	to	opioid,	methadone,	and	buprenorphine	exposure,	but	it	is	very	preliminary	in	nature	and	provides	little	direction	for	change.		Across	the	literature,	these	women	have	reported	feeling	ostracized	and	misunderstood,	consistently	being	met	with	misconceptions	and	prejudicial	mindsets.	This	research	consistently	reveals	that	pregnant	and	postpartum	women	with	opioid	use	disorders	experience	judgment,	indifference,	stigmatization,	embarrassment,	and	anxiety	when	interacting	with	healthcare	providers.	They	experience	shaming	verbal	and	nonverbal	language	of	healthcare	staff,	subjective	NAS	scoring,	and	the	exclusion	of	the	mother	from	participating	in	the	treatment	plan	for	both	herself	and	for	her	baby.	They	also	describe	fears	surrounding	child	protective	service	involvement,	particularly	surrounding	the	secretive	nature	of	mandated	reporting	procedures,	the	sharing	of	medical	information,	and	lack	of	transparency	in	the	discharge	planning	process.	The	power	and	
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influence	of	language	choice,	perception,	and	social	stigma	becomes	the	focus	forefront,	rather	than	attachment	and	bonding	between	the	mother	and	the	infant	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Goodyear-Smith	&	Buetow,	2001;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).	The	existing	research,	in	fact,	corroborates	these	experiences.	The	literature	reveals	that	health	care	providers	acknowledge	having	negative,	judgmental	thoughts	and	feelings	toward	pregnant	and	postpartum	women	with	opioid	use	disorders.	They	also	report	experiencing	heightened	stress	when	working	with	this	population	due	to	maternal	defensiveness,	difficulty	with	engagement,	and	concern	for	the	baby’s	wellbeing	(Fraser	et	al.,	2007;	Maguire,	Webb,	Passmore,	&	Cline,	2012;	Murphy-Oikonen,	Brownlee,	Montelpare,	&	Gerlach,	2010).		It	has	become	clear	that	there	is	a	cyclical	relationship	between	the	perceptions	of	both	the	mothers	and	the	providers.	It	is	emotionally	grueling	for	a	mother	to	watch	her	infant	experience	withdrawal.	Many	women	in	this	position	feel	tremendous	guilt	and	blame	themselves	for	being	the	cause	of	their	baby’s	distress.	Unfortunately,	many	of	these	women	are	further	hindered	by	limited	coping	skills	to	help	them	process	the	situation.	At	this	point,	maladaptive	coping	mechanisms	come	into	play,	including	defensiveness,	disengagement,	and	decreased	or	lack	of	visitation.	In	turn,	healthcare	providers	are	perceiving	these	behaviors	indifference	and	lack	of	maternal	investment	in	the	baby,	impacting	the	way	in	which	they	interact	with	these	women	and	how	they	include	them	in	medical	care	planning.	And	so	the	cycle	continues,	as	these	mothers	feel	further	ostracized,	
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judged,	and	discouraged	from	interacting	with	their	infants	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).	Unfortunately,	these	recurring	patterns	of	stigma	and	misconception	become	the	foundation	of	a	socially-constructed	barrier	to	early	attachment	development.	The	combination	of	these	challenges	and	deterrents	results	in	reduced	or	complete	lack	of	visitation	by	the	mother.	This	is	detrimental	to	the	mother	and	infant	both	independently	and	as	a	dyad.	The	mother	misses	out	on	the	opportunity	to	develop	the	attachment	bond	and	learn	her	child’s	feeding	and	soothing	preferences.	Even	when	she	does	visit,	her	interactions	may	be	more	depressed	or	anxious,	which	negative	influences	attachment,	bonding,	and	maternal	confidence	(Cleveland,	2013;	Cleveland	&	Bonugli,	2014;	Cleveland	et	al.,	2016;	Dimirci	et	al.,	2015;	Holbrook,	2015;	Holbrook	&	Nguyen,	2015;	Howard,	2015;	Howard,	2016;	Jones	et	al.,	2008;	Mattocks	et	al.,	2017;	Stengel,	2014;	Stone,	2015;	Suchman	&	Luthar,	2000).				 Without	regular	visitation	and	interaction	with	the	mother,	the	infant	is	unable	to	develop	a	secure	attachment.	Infants	who	lack	secure	attachment	to	their	caregiver,	the	mother	in	this	case,	are	likely	to	be	more	irritable	and	cry	more	often	than	those	infants	who	have	had	the	opportunity	to	develop	that	secure	attachment.	This	increases	the	risk	of	maternal	stress	which	can	be	a	potential	trigger	for	substance	use	relapse	and	child	abuse	or	neglect.	This	cycle	also	prevents	the	utilization	of	the	efficacious	nonpharmacological	treatment	approaches,	all	of	which	involve	bonding	and	attachment	development	(Kim,	Fonagy,	Allen,	&	Strathearn,	2014;	Parolin	&	Simonelli,	2016;	Suchman	&	Luthar,	2000).		
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	 This	comprehensive	review	of	the	literature	has	identified	stigma	as	the	biggest	inhibiting	factor	to	bond-development	between	mother	and	baby.	These	psychosocial	factors	and	the	corresponding	benefits	directly	coincide	with	the	principles	of	attachment	theory	and	the	development	of	secure	attachment	with	a	caregiver.	The	following	chapter	will	thoroughly	describe	attachment	theory,	which	is	arguably	the	most	renowned	and	empirically-supported	philosophy	of	human	relationship	development	and	explore	the	way	in	which	it	relates	to	mothers	and	infants	impacted	by	opioid	use	disorders.		
CASE	STUDY	VIGNETTE	
	“Oh	my	God,	I’m	pregnant,”	Kiana	repeated	to	herself.	An	ultrasound	revealed	
that	Kiana	was	about	12	weeks	into	her	pregnancy.	As	Kiana	lowered	her	head	in	utter	
shock	and	disbelief,	her	eyes	were	immediately	drawn	to	the	track	marks	on	her	arms.	
She	quickly	crossed	her	arms	across	her	chest	to	conceal	the	proof	that	she’s	“one	of	those	people.”	Kiana	silently	wondered	what	the	doctor	thought	of	her	as	she	stood	in	
front	of	her,	wearing	her	neatly	pressed	white	lab	coat	and	expensive-looking	black	
leather	flats.		
Kiana’s	mind	started	to	wander	into	the	foreshadowing	of	coming	back	to	this	
very	hospital,	six	months	from	now,	to	give	birth	to	her	baby.	She	imagined	the	nurses	
whispering	soul-crushing	comments	about	her	being	undeserving	of	motherhood.	She	
imagined	being	restricted	from	visiting	her	baby	in	the	NICU,	never	getting	to	hold	or	
breastfeed	her	firstborn	child.	She	imagined	a	child	protective	services	worker	taking	
her	baby	from	her	arms	while	the	staff	stared	at	her	with	disdain.	What	was	once	a	
lifelong	dream	has	now	become	shrouded	in	fear.		
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CHAPTER	III:	THEORETICAL	FRAMEWORK	
THE	INTERSECTION	OF	PERINATAL	OPIOID	USE	DISORDERS	AND	ATTACHMENT	THEORY		 Attachment	theory	focuses	on	the	active,	ongoing	dynamics	of	interpersonal	relationships	between	human	beings	(Ainsworth,	1964).	Psychoanalytic	theory	concentrates	on	both	healthy	and	maladaptive	aspects	of	the	human	personality	and	interrelationships.	Attachment	theory	examines	how	we	develop,	internalize,	and	function	within	these	relationships	(Bowlby,	1969).	The	theory	of	attachment	is	not	just	philosophical	in	nature;	there	are	several	indications	of	neurobiology	that	support	humans’	biologically-driven	instinct	to	cultivate	social	relationships	and	interactions	(Bowlby,	1957).	Evidence	shows	that	there	are	neurological	connections	to	attachment	theory,	including	autonomic	responses,	which	regulate	heart	rate	and	respiration,	and	hypothalamic-pituitary-adrenal	axis	activity,	which	regulates	stress	(Bowlby,	1969).	The	way	in	which	a	person	experiences	and	internalizes	attachment	relationships	is	neurologically	catalytic.	Furthermore,	these	memories	become	the	hardwiring	for	interpersonal	connections	and	bonds	(Applegate	&	Shapiro,	2005).		The	empirical	research	uncovered	has	revealed	that	incorporating	psychosocial	factors	like	breastfeeding,	bonding,	swaddling,	cuddling,	and	family	involvement	improves	outcomes	for	infants	with	intrauterine	opioid	exposure.	The	literature	also	reveals	that	additional	psychosocial	factors,	like	nurturing,	supportive,	stable	homes	with	social	and	family	protective	factors,	provide	further	improved	short-	and	long-term	physical	and	behavioral	outcomes	for	these	infants	and	their	families.	Each	of	these	factors,	though	individually	beneficial,	are	all	linked	by	an	extremely	significant	common	denominator.	They	are	all	components	of	early	attachment	development.		
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EARLY	ATTACHMENT	DEVELOPMENT	Early	attachment	development,	though	inherently	a	natural	part	of	the	child	rearing	process,	does	require	intentional	interactions	to	occur	between	the	baby	and	primary	caregiver.	Bowlby	defines	attachment	behavior	as	“any	form	of	behaviour	that	results	in	a	person	attaining	or	maintaining	proximity	to	some	other	clearly	identified	individual	who	is	conceived	as	better	able	to	cope	with	the	world”	(Bowlby,	1988,	page	26-27).	There	can	be	multiple	attachment	relationships	between	the	infant	and	caregivers.	Generally	speaking,	the	principal	attachment	figure	is	the	mother,	as	she	is	the	closest	possible	figure	to	the	birth	itself.	Subsidiary	attachment	figures	include	many	other	human	beings	who	interact	with	the	infant.	These	figures	are	distinct	from	the	primary	attachment	figure	and	generally	come	in	the	form	of	playmates	and	substitute	or	short-term	caregivers.	These	figures,	though	they	can	be	fleeting	in	nature,	are	also	an	integral	part	of	the	infant’s	attachment	development.	These	figures	exist	outside	of	the	safety	nest	created	by	the	primary	attachment	figure	and	provide	the	infant	with	the	opportunity	to	explore	and	test	limits.	At	any	point	in	which	the	infant	becomes	startled,	hurt,	or	uncomfortable	with	the	subsidiary	figure,	he	will	instinctively	seek	out	and	retreat	to	the	primary	caregiver	(Bowlby,	1969).		Although	there	are	certainly	many	instances	where	the	non-maternal	caregiver	can	develop	a	strong	primary	bond	with	the	infant,	there	are	certain	hormonal	aspects	of	the	mother/infant	relationship	that	make	this	bond	occur	more	easily	than	with	another	caregiver	(Bowlby,	1969).	Oxytocin,	a	powerful	maternal	hormone	that	acts	as	a	bonding	neurotransmitter	within	the	brain,	is	triggered	within	the	mother	when	the	infant	engages	with	or	touches	the	mother	(Klaus	&	Kennell,	1976).	Eye	contact	between	the	infant	and	
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mother	is	most	successful	when	within	12	inches	of	each	other’s	faces,	as	this	is	the	proximity	in	which	an	infant’s	vision	can	clearly	identify	the	mother’s	face	(Klaus	&	Kennell,	1976).		The	generation	of	oxytocin	is	just	one	of	several	hormonal	bonding	interactions	that	occur	within	the	mother/infant	relationship.	Klaus	and	Kennell	(1976)	identified	and	described	nine	bonding	interactions	that	are	initiated	by	the	mother,	including	touch,	eye	contact,	high-pitched	voice,	entrainment,	time,	lymphocytes	(breastmilk	nutrient),	bacterial	nasal	flora,	odor,	and	heat.	Klaus	and	Kennell	(1976)	also	identified	and	described	six	interactions	that	are	initiated	by	the	infant,	including	eye	contact,	cry,	oxytocin	(maternal	hormone),	prolactin	(hormone	that	encourages	breast	milk	production),	odor,	and	entrainment.	The	increase	in	oxytocin	is	especially	significant,	as	elevations	in	oxytocin	during	bonding	have	been	clinically	shown	to	increase	maternal	euphoria,	love,	and	attachment	to	the	infant	(Klaus,	1998).	The	importance	of	identifying	the	mother/infant	relationship	is	not	intended	to	diminish	the	relevance	or	worth	of	other	primary	attachment	figures,	but	rather	to	emphasize	the	value	of	the	maternal	role	regardless	of	the	mother’s	imperfections.	This	is	especially	important	to	consider	in	the	context	of	early	attachment	bonding	between	mother/infant	dyads	impacted	by	opioid	use	disorders.	The	infant	loves,	desires,	and	craves	the	mother	no	matter	what.	She	is	always	important,	and	she	is	always	needed.		Eye	contact,	physical	contact,	and	verbal	contact	are	all	key	elements	of	attachment	development	between	the	mother	and	infant	(Bowlby,	1977).	To	develop	a	strong	attachment	bond,	these	activities	must	be	consistent	and	reliable.	Consistency	is	predictable	and	inherently	safe.	During	generally	healthy,	uncomplicated	pregnancies,	
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infants	consistently	receive	nutrition	through	the	umbilical	cord	without	interruption.	Continuing	that	consistency	in	feeding	while	infants	are	still	too	small	to	provide	for	themselves	makes	them	feel	safe	(Bowlby,	1969).	Once	consistency	is	established,	the	infants	feel	safe	knowing	that	they	are	likely	to	receive	the	same	response	from	the	same	stimulus	in	the	future.	For	example,	infants	know	that	they	will	be	picked	up	and	fed	when	they	cry	(Bowlby,	1958).		Although	there	are	several	generalizable	infant	cues	(i.e.	cries	when	hungry),	each	infant	communicates	differently	than	the	other.	Neonatal	abstinence	syndrome	can	play	a	significant	role	in	this	attachment	development	and	the	way	in	which	babies	interact	with	their	attachment	figures.	Symptoms	of	NAS	directly	impact	the	way	in	which	the	baby	eats,	sleeps,	and	cries.	Infants	initially	utilize	crying	as	a	form	of	expression,	but	eventually	crying	becomes	the	infant’s	primary	mode	of	communication	with	the	mother	(Bell	&	Ainsworth,	1972;	Bowlby,	1969).	This	is	the	infant’s	primary	and	initial	form	of	communication	with	the	mother.	The	infant’s	cry	initiates	physiological	responses	within	the	mother	that	induce	breastmilk	production.	A	mother	can	develop	an	incredibly	strong	bond	with	her	child	as	she	learns	to	speak	her	child’s	language	(Klaus	&	Kennell,	1967	&	Tronick,	1989).		Holding	the	infant	close	to	the	chest	fosters	the	feeling	to	security	by	mitigating	the	infant’s	fear	of	openness.	The	infant	can	safely	and	confidently	explore	the	world	around	him	while	feeling	his	mother	within	reach.	Kangaroo	Care,	which	originated	in	Bogota,	Colombia	as	a	necessary	means	to	compensate	for	shortage	in	equipment,	involves	skin	to	skin	contact	in	the	critical	care	setting	(Johnson,	2013).	Kangaroo	Care	creates	the	
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desirable	heat,	scent,	eye	contact,	touch,	prolactin,	oxytocin,	as	described	by	Klaus	and	Kennell	(1976).		Primary	object	sucking	and	clinging	theory,	also	developed	by	Bowlby,	asserts	that	infants	have	an	instinctual	need	to	suck	for	nutrition	and	cling	for	affection.	These	needs	can	be	observed	in	infant	behaviors	when	the	infant	exhibits	the	rooting	reflex,	which	refers	to	the	way	in	which	an	infant	seeks	to	find	an	object	that	touches	his	or	her	face,	especially	near	the	mouth	(Bowlby,	1969).	Production	of	prolactin,	a	protein-based	bonding	hormone	that	enables	a	mother	to	produce	breastmilk,	is	triggered	within	the	mother	when	the	infant	engages	with	or	touches	the	mother	(Klaus	&	Kennell,	1967).	Though	breastfeeding	is	not	specifically	required	to	develop	a	strong	attachment	bond,	it	is	ideal.	Breastmilk	has	substantial	nutritional	benefits	and	contains	lymphocytes	and	docosahexaenoic	acid	(DHA)	omega-3	fats	(Klaus	&	Kennell,	1967;	Andreas,	Kampmann,	&	Le-Doare,	2015).	These	nutrients	promote	neurodevelopment	and	reduce	risk	for	affective	and	developmental	disorders	(Liu,	Leung,	&	Yang,	2014;	Andreas	et	al.,	2015).		
THE	IMPACT	OF	ATTACHMENT	DEVELOPMENT	ACROSS	THE	LIFESPAN	Bowlby	posited	that	attachment	development	was	a	very	black	and	white	process:	either	the	attachment	bond	existed,	or	it	did	not.	Ainsworth	further	elaborated	upon	this	concept	and	noted	that	there	are	specific	intervals	of	attachment	bonds	that	exist,	which	she	identified	as	attachment	patterns,	or	styles,	in	the	1950s.	Attachment	patterns,	or	styles,	refer	to	infant	behaviors	that	correlate	to	the	way	the	infant	experiences	a	relationship	with	an	attachment	figure.	Attachment	patterns	are	developed	in	infancy	and	are	often	strong	indications	of	attachment	pattern	development	in	adulthood	(Ainsworth	et	al.,	1978;	Bowlby,	1969).		
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ATTACHMENT	PATTERNS	IN	INFANCY	Behaviors	of	attachment	patterns	in	infancy	are	indicative	of	two	things:	the	behaviors	through	which	the	infant	signals	the	mother’s	attention	and	the	infant’s	attainment	and	maintenance	of	the	desired	contact	(Bell	&	Ainsworth,	1972).	Based	on	Ainsworth’s	discoveries,	infants	ultimately	develop	one	of	three	attachment	styles:	secure,	anxious-avoidant,	anxious-resistant	(Ainsworth	et	al.,	1978).		Of	note,	it	is	important	to	consider	four	factors	prior	to	making	a	determination	regarding	a	child’s	attachment	style:	the	location	of	the	primary	attachment	figure,	the	location	of	any	subsidiary	attachment	figures,	the	physical	environment,	and	the	child’s	medical	status.	Any	individual	or	combination	of	these	factors	can	vastly	impact	the	behavior	of	an	infant	and	may	not	be	indicative	of	an	attachment	pattern	(Bowlby,	1969).	Ainsworth	identified	one	specific	category	for	secure	attachment	and	three	distinct	categories	of	insecure	attachment:	anxious-resistant,	anxious-avoidant,	and	disorganized-disoriented	(Ainsworth	et	al.,	1978).		Securely	attached	infants	will	explore	new	surroundings	with	curiosity	and	interest	while	occasionally	looking	back	at	the	mother	for	support.	This	infant	will	develop	strong	coping	methods	and	adaptability	to	unfamiliar,	uncomfortable	situations.		Secure	attachment	is	developed	from	two	factors	–	the	mother’s	responsiveness	to	the	infant’s	signals	and	the	nature	and	quality	of	the	time	spent	between	the	mother	and	the	infant.	A	mother	who	quickly	picks	up	her	crying	infant,	but	then	does	not	engage	with	him	may	develop	a	weaker	attachment	bond	with	her	child	when	compared	to	a	mother	who	quickly	picks	up	her	crying	infant	and	then	subsequently	engages	with	him	through	eye	contact	and	speech.	The	quality	of	the	time	spent	together	is	very	important.	This	is	not	just	about	
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blindly	responding	to	the	child’s	needs	or	enabling	behavior,	it’s	about	developing	this	sense	of	closeness	that	makes	the	infant	feel	safe	and	secure.	Allowing	the	child	to	“cry	it	out”	is	an	ineffective	way	to	teach	the	infant	to	self-soothe.	Infants	develop	a	secure	attachment	when	engaged	with	primary	attachment	figures	who	are	sensitive	and	loving	(Ainsworth	et	al.,	1978;	Bowlby,	1977).	Other	psychoanalytic	disciplines	may	refer	to	similar	developmental	outcomes	as	strong	ego,	basic	trust	(versus	mistrust),	mature	dependence,	the	true	self,	and	internalization	of	the	good	object	(Bowlby,	1977).				Infants	who	develop	secure	attachment	with	the	primary	caregiver(s)	are	generally	easier	to	soothe	and	exhibit	less	intense	reactions	to	stressful	stimuli,	as	they	have	been	forded	with	predictability	and	safety.	The	mutually	experienced	increase	in	oxytocin	levels	fosters	a	close,	loving	bond	as	well	as	a	decrease	in	occurrence	of	postpartum	depression	(Klaus	&	Kennell,	1967).	These	infants	are	also	more	likely	to	explore	their	surroundings,	thus	stimulating	neurodevelopment	and	meeting	developmental	milestones	(Bowlby,	1969).		Ainsworth	identified	three	distinct	categories	of	insecure	attachment:	anxious-resistant,	anxious-avoidant,	and	disorganized-disoriented	Anxious-resistant	attachment	patterns	are	characterized	by	ambivalence	toward	attachment	entities	and	surroundings.	Infants	who	develop	anxious-resistant	attachment	styles	will	express	significant	emotional	distress	when	the	mother	leaves,	only	to	ignore	her	upon	engagement.	The	infant	may	pay	more	attention	to	a	subsidiary	attachment	figure	than	the	primary.	The	infant’s	behavior	toward	the	primary	attachment	figure	seesaws	from	clingy	to	irate	in	response	to	perceived	neglect	(Ainsworth	et	al.,	1978;	Mirick	&	Steenrod,	2016).	Infants	develop	anxious-resistant	attachment	when	in	the	care	of	a	primary	attachment	figure	who	is	
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emotionally	unavailable	and	unresponsive	is	experienced	as	insensitive	and	even	rejecting	(Tracy	&	Ainsworth,	1981;	Bowlby,	1969).	Infants	who	develop	anxious-resistant	attachment	styles	may	end	up	developing	transient	attachment,	which	involves	fleeting	interest	in	other	humans	and	surroundings.	In	some	cases,	these	infants	stop	attaching	to	other	humans	and	cultivate	a	self-centered,	preoccupation	with	material	objects,	like	candy,	food,	and	toys	that	provide	them	with	pleasure	and	self-regulation	(Bowlby,	1969).			 The	anxious-avoidant	infant,	on	the	other	hand,	does	not	show	any	particularly	protesting	behaviors	when	the	primary	caregiver	leaves	the	infant’s	sight.	However,	when	the	primary	caregiver	returns,	this	infant	will	simply	show	disinterest	in	her	presence.	The	infant’s	response	is	neither	angry	nor	excited	in	nature.	Sometimes,	specific	efforts	to	ignore	the	mother	(such	as	turning	the	head	away,	using	the	arms	to	push	off	the	mother)	are	noticed.	Infants	develop	anxious-	avoidant	attachment	when	in	the	care	of	a	primary	attachment	figures	who	is	insensitive	and	inconsistent	(Ainsworth	et	al.,	1978;	Mirick	&	Steenrod,	2016).			 The	final	attachment	pattern,	disorganized-disoriented,	was	not	originally	included	in	Ainsworth’s	literature.	She	identified	and	added	this	attachment	style	later	in	order	to	accurately	identify	more	extreme,	inexplicable	attachment	behaviors.	These	behaviors	include	perceived	inability	to	function	within	the	environment	in	the	context	of	the	caregiver.	Infants	who	develop	disorganized-disoriented	attachment	are	consistently	alternating	between	seeking	attachment,	attention,	and	bonding	with	the	caregiver	and	freezing,	avoiding,	and	sometimes	even	lashing	out	against	a	caregiver	without	necessarily	having	a	specific	invoking	stimulus.	These	infants	regularly	exhibit	contradictory	behaviors	
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due	to	inconsistent,	unpredictable	interaction	with	the	caregiver	(Ainsworth	et	al.,	1978;	Mirick	&	Steenrod,	2016).		
ATTACHMENT	PATTERNS	IN	ADULTHOOD	On	the	other	hand,	infants	unable	to	develop	secure	attachment	struggle	with	interpersonal	relationship	difficulties	as	adults.	In	the	1980s,	Cindy	Hazan	and	Phillip	Shaver	extended	this	research	to	adults	and	found	significant	similarities	in	attachment	patterns	between	adults	and	children	(Hazan	&	Shaver,	1994).	As	the	child	makes	his	way	into	adulthood,	he	or	she	may	exhibit	behavioral	and/or	social	difficulties	(Flores,	2005).	They	experience	greater	challenges	with	developing	healthy	platonic	and	romantic	relationships	and	engaging	in	intimacy	with	peers.	Secure	attachment	development	can	be	hindered	by	abuse,	neglect,	trauma,	and	poor	caregiver	consistency	and	reliability.	Adults	who	struggle	with	attachment	development	may	exhibit	overwhelming,	maladaptive,	irrational	behaviors	as	a	way	of	demanding	love	and	attention	while	simultaneously	playing	a	resentful,	extreme	caretaker	role.	In	rare	cases,	sociopathology	can	arise	from	extreme	attachment	issues	(Bowlby,	1977).		Infants	who	developed	secure	attachment	to	a	primary	caregiver	generally	transition	into	becoming	well-adjusted	adolescents	and	adults	and	have	the	ability	to	fulfill	the	natural	human	desire	to	develop	trusting	relationships.	Securely	attached	adolescents	and	adults	are	cooperative,	empathetic,	and	easily	engaged	with	others.	Well-adjusted	adults	are	also	characterized	by	having	established	coping	skills	and	are	successful	with	affect	regulation	(Bowlby,	1977).	Research	indicates	that	infants	who	were	breastfed,	and	engaged	during	breastfeeding,	are	less	likely	to	internalize	feelings	of	anxiety,	depression,	and	other	somatic	symptoms	as	adults	(Liu	et	al.,	2014).		
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Three	distinct	categories	of	insecure	attachment	in	adulthood:	dismissive-avoidant,	anxious-preoccupied,	and	fearful-avoidant.	Dismissive-avoidant	adults	often	feel	as	though	achieving	and	maintaining	relational	independence	is	more	important	than	developing	closer,	more	intimate	relationships.	They	have	a	strong	self-perception	and	a	lower	value	perception	of	others	(Hazan	&	Shaver,	1994).	Anxious-preoccupied	adults	are	characterized	by	opposite	relational	worldviews.	They	perceive	themselves	to	have	a	lower	self-value,	while	others	are	perceived	more	positively	with	a	higher	value.	These	adults	find	that	they	crave	extremely	intimate	relationships	with	others,	and	often	become	disheartened	when	this	need	is	not	met	(Hazan	&	Shaver,	1994).	Fearful-avoidant	adults	experience	a	combination	of	the	dismissive-avoidant	and	anxious-preoccupied	attachment	patterns.	Adults	with	this	attachment	style	are	often	unsure	of	how	they	want	to	experience	relationships	and	are	further	confused	by	how	to	determine	or	achieve	their	desired	relational	goal.	This	fluctuating	and	alternating	approach	to	relationships	with	others	can	often	inhibit	the	creation	of	healthy,	stable	relationships	in	general.		Life	experiences	that	contribute	to	fearful-avoidant	adult	attachment	styles	can	often	be	associated	with	complex	trauma	(Hazan	&	Shaver,	1994).	When	the	need	for	self-regulation,	security,	and	predictability	is	not	met,	the	insecurely	attached	person	looks	to	compensatory	measures.	This	unconscious	search	for	compensatory	measures	can	manifest	in	several	different	ways,	including	addiction.	The	addiction,	however,	ultimately	provides	the	opposite	of	self-regulation,	security	and	predictability.	It	is	an	attempt	to	self-repair	that	always	fails.	It	is	rare	to	meet	a	person	with	substance	dependency	who	does	
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not	also	have	some	form	of	attachment	trauma	history	(Flores,	2005;	Parolin	&	Simonelli,	2016).	
MATERNAL/INFANT	ATTACHMENT	DEVELOPMENT	IN	THE	HOSPITAL	SETTING	As	previously	mentioned,	early	attachment	development,	though	an	inherently	natural	part	of	the	child	rearing	process,	does	require	intentional	interactions	to	occur	between	the	baby	and	primary	caregiver.	These	interactions	are	especially	challenging	in	the	hospital	setting,	which	can	act	as	a	barrier	to	attachment	itself.	Hospitals	are	generally	sterile,	uncomfortable	environments	where	medical	treatment	and	sanitation	is,	logically,	prioritized	over	relaxation	and	coziness.	In	many	cases,	curtains	between	patients	are	the	extent	to	which	privacy	exists.	There	are	limited	options	for	personalized	bonding	or	free	range	of	motion,	pushing	away	from	an	attachment-fostering	atmosphere.		As	empirical	evidence	continues	to	support	the	significant	relationship	between	early	attachment	bonding	and	physical,	mental,	and	interpersonal	health	outcomes,	researchers	are	beginning	to	explore	new	approaches	to	cultivating	these	bonds.	For	example,	an	adaption	of	child-parent	psychotherapy	(CPP),	an	attachment-based	psychotherapeutic	intervention,	is	currently	being	piloted	in	a	NICU	setting	in	a	California-based	study.	This	pilot	program	aims	to	evaluate	the	efficacy	of	this	NICU-specific	adaption	of	CPP	in	improving	infant/parent	bonds	(Lakatos,	Matic,	Carson,	&	Williams,	2019).		These	types	of	studies,	although	incredibly	important	and	vital	to	improving	infant/parent	relational	outcomes,		fail	to	address	the	specific	needs	of	mothers	and	infants	impacted	by	opioid	use	disorders,	a	remarkably	stigmatized,	vulnerable	population.	The	way	in	which	a	mother	develops	a	relationship	and	bonds	with	her	infant	with	NAS	has	its	own	unique	challenges.	Infants	being	treated	for	NAS	also	have	difficulties	communicating	
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effective	cues	to	their	caregivers,	making	it	more	challenging	than	usual	to	console	them.	The	sound	of	their	cries,	for	example,	is	very	different	than	other	newborns.	Their	cries	are	louder	and	higher	pitched.	They	are	also	much	more	difficult	to	console	(MaGuire	et	al.,	2016).		 		 Though	the	attachment	styles	identified	by	Ainsworth	have	clear	differences,	they	may	be	difficult	to	appropriately	identify	in	the	baby	being	treated	for	NAS.	For	example,	because	symptoms	of	NAS	resemble	behaviors	linked	to	insecure	attachment,	such	as	irritability,	agitation,	and	excessive	crying,	it	may	be	difficult	to	identify	how	the	infant’s	attachment	to	the	mother	is	developing	during	NAS	treatment.	Even	if	a	mother	visits	her	infant	every	day	to	support	a	secure	attachment,	the	benefits	of	her	efforts	may	not	be	evident	until	after	the	baby’s	course	of	treatment	is	finished.	Representations	and	relationships	with	attachment	figures	in	childhood	perseverate	into	adulthood.	Consequently,	the	internalization	of	these	relationships	ultimately	becomes	the	self-model	(Bowlby,	1977).	By	diminishing	the	opportunity	to	provide	education	and	foster	healthy	attachments	between	these	mothers	and	their	infants,	providers	are	simultaneously,	and	drastically,	increasing	risk	of	harm	and	perpetuating	this	cycle.	The	need	for	an	evidence-informed	approach	like	the	PARTNER	model	is	evident.		 	
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CHAPTER	IV:	METHODOLOGY	
PURPOSE	AND	SIGNIFICANCE	The	purpose	of	this	dissertation	is	to	develop	an	original,	multidisciplinary	practice	model	for	providers	working	with	mothers	and	infants	impacted	by	opioid	use	disorders.	A	thorough	review,	synthesis,	and	critical	analysis	of	the	literature	has	revealed	that	there	are	several	treatment	approaches	for	pregnant	and	postpartum	women	with	opioid	disorders,	as	well	as	infants	diagnosed	with	NAS.	The	literature	review	has	also	revealed	that	maternal	engagement,	support	and	care,	all	of	which	are	empirically	shown	to	improve	outcomes	for	both	the	mothers	and	infants	themselves,	are	consistently	being	obstructed	by	barriers	to	care.	The	most	commonly	identified	barriers	to	achieving	these	improved	outcomes	are	sociocultural	constructs	including	stigma,	judgment,	and	exclusion.	These	psychosocial	factors	do	not	coincide	with	the	disease-model	approach	of	medicine	and	are	substantially	hindering	the	delivery	of	quality,	unbiased	care.	Effective	treatment	approaches	and	barriers	to	care	have	been	clearly	identified	in	the	existing	literature,	but	a	missing	piece	to	this	complex	puzzle	remains:	how	can	providers	work	with	pregnant	and	postpartum	women	and	their	infants	in	a	way	that	reduces	stigma	and	fosters	attachment?	The	PARTNER	model	bridges	this	gap	in	the	literature	in	an	innovative,	practical,	and	approachable	way.	It	embraces	the	humanistic	side	of	this	delicate	relationships	that	does	not	exist	in	the	medical	treatment	models	guiding	healthcare	practices.	The	current	literature,	as	well	as	this	identified	gap	in	the	literature,	support	the	need	for	a	practice	model	that	provides	guidelines	for	providers.	The	PARTNER	model	has	been	designed	to	guide	providers	in	providing	ethical,	humanistic,	attachment-focused	care	to	mothers	and	infants	like	Kiana	and	William.		
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PRACTICE	MODEL	AND	COMPOSITE	CASE	STUDY	DESIGN	The	PARTNER	model	takes	all	the	aforementioned	factors	into	consideration	and	equips	healthcare	providers	with	the	education	and	guidance	needed	to	not	only	create	a	partnership	between	the	mother	and	the	infant,	the	mother	and	providers	as	well.	The	PARTNER	model	is	comprised	of	seven	key	elements	of	attachment-focused	care,	including:	1. Person-Centered		2. Attachment-Informed		3. Risk	Reduction	4. Trauma-Informed		5. Neutrality	6. Empowerment	7. Reinforcement	This	model	has	been	designed	to	provide	guidance	to	providers	working	pregnant	and	postpartum	women	with	opioid	use	disorders.	“Providers”	include	licensed	professionals	working	in	a	healthcare	setting	including,	but	not	limited	to,	physicians,	nurse	practitioners,	physician	assistants,	psychologists,	registered	nurses,	and	clinical	social	workers	(Code	of	Federal	Regulations,	2012).		This	model	has	been	developed	based	on	the	review,	synthesis,	and	critical	analysis	of	the	current	literature	along	with	the	integration	of	relevant	practice	knowledge,	theory,	and	research.		Each	element	is	derived	from	evidence-based	practices	with	modifications	to	meet	the	unique	needs	of	this	unique	population.	There	are	no	other	constraints	in	terms	of	gender	identity,	race,	age,	or	socioeconomic	status.	However,	there	are	recommendations	for	consideration	of	these	factors	incorporated	into	the	model.		
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Composite	case	vignettes,	informed	by	clinical	experience	and	empirical	literature,	have	been	incorporated	throughout	this	dissertation.	These	case	vignettes	tell	the	story	of	Kiana,	a	23-year-old	black,	heterosexual,	cisgender	woman	with	a	perinatal	opioid	use	disorder.	Pertinent	elements	of	Kiana’s	history	have	been	integrated	throughout	the	literature	review,	illuminating	and	connecting	her	story	to	the	concepts	that	set	the	foundation	for	the	PARTNER	model.	Kiana’s	story	continues	after	the	introduction	of	the	PARTNER	model,	picking	back	up	from	where	it	stopped	at	the	end	of	the	literature	review.		
The	story	of	Kiana’s	journey	through	pregnancy	and	the	birth	of	her	baby,	William,	brings	life	and	connection	to	each	element	of	the	PARTNER	model.	The	PARTNER	model	has	been	specifically	designed	with	patients	like	Kiana	and	William	in	mind,	whose	story	is	similar	to	many	of	the	women	and	babies	impacted	by	perinatal	opioid	addiction.	Identifying	areas	of	antiquation	and	integrating	strengths-based	interventions	emphasizes	the	importance	of	promoting	attachment	between	a	mother	and	her	infant,	provides	a	person-centered	framework	from	which	to	work,	and	fosters	insight	into	and	mitigation	of	socially-constructed	barriers	that	deepen	the	divide	between	“us”	and	“them.”		
	 	
 63 
CHAPTER	V:	PRACTICE	MODEL	AND	CASE	STUDY	
INTRODUCTION	TO	THE	PARTNER	MODEL		 This	chapter	will	provide	a	layout	of	the	PARTNER	model	including	an	overview,	key	elements,	significance,	and	application	to	practice.	The	following	chapter	will	include	a	case	study	that	provides	examples	of	how	each	of	the	elements	should	be	integrated	into	healthcare	provider	practice.	The	PARTNER	model	is	comprised	of	seven	key	elements	of	attachment-focused	care,	including:	1. Person-Centered		2. Attachment-Informed	3. Risk	Reduction	4. Trauma-Informed	5. Neutrality	6. Empowerment	7. Reinforcement	All	of	these	elements	are	intended	to	be	integrated	simultaneously	and	seamlessly	into	care.	The	model	emerged	from	an	understanding	of	risk	factors	for	opioid	use	disorder,	barriers	to	prenatal/postnatal	care,	and	ways	to	address	these	issues	with	a	focus	on	fostering	attachment	not	just	by	developing	a	partnership	between	mother	and	baby,	but	also	between	mother	and	the	care	providers.	Each	element	has	a	common	goal	of	educating,	reducing	stigma,	and	fostering	attachment.	These	components	can	certainly	be	applied	to	anyone	with	a	history	of	addiction,	but	this	model	is	specifically	designed	for	pregnant	and	postpartum	women	currently	struggling	with	addiction,	as	it	specifically	addresses	the	unique	needs	of	this	population	as	uncovered	in	the	literature.		
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THE	PARTNER	MODEL	IN	ACTION		 Throughout	the	PARTNER	model	analysis,	vignettes	from	Kiana’s	composite	case	study	are	incorporated	to	illustrate	how	the	elements	of	the	PARTNER	model		are	implemented	in	practice.	To	reintroduce	Kiana,	she	is	a	23-year-old	black,	heterosexual,	cisgender	woman	with	a	perinatal	opioid	use	disorder.	Kiana	currently	lives	in	Philadelphia	with	her	mother	and	two	younger	sisters	and	works	long,	late-night	hours	a	restaurant.	She	has	several	risk	factors	linked	to	substance	use	disorders,	including	a	family	history	of	alcohol	abuse,	mental	illness,	and	domestic	violence,	all	of	which	contribute	to	Kiana’s	ACE	score	of	8/10.	Kiana	has	also	been	diagnosed	with	depression	and	has	experienced	sexual	violence	in	adulthood.		Kiana	was	first	introduced	to	opiates	at	age	20,	when	she	was	given	a	prescription	for	Percocet	after	getting	into	a	car	accident.	Without	having	any	education	on	opioid	risks,	she	took	the	Percocet	prescription	every	day	for	two	months.	Unfortunately,	a	handful	of	missed	opportunities	helped	to	create	a	pipeline	to	addiction.	Kiana	never	got	psychoeducation	on	the	risk	of	opioids	or	an	evaluation	for	opioid	dependency.	Kiana	was	met	with	stigma	and	judgment	rather	than	support	and	unbiased	care.	It	was	only	a	matter	of	weeks	before	Kiana	became	physically	dependent	and	behaviorally	addicted	to	opioids.	Eventually,	Kiana	transitioned	from	Percocet	to	heroin.		Three	years	after	being	introduced	to	opiates,	Kiana	experienced	her	first	overdose.	She	was	treated	with	NARCAN	and	brought	to	the	hospital	for	an	evaluation	and	workup.	It	was	during	this	emergency	department	visit	that	Kiana	found	out	she	was	12	weeks	pregnant.	Kiana’s	story	continues	from	here,	at	which	time	she	is	treated	by	providers	who	are	working	from	the	PARTNER	model	approach.	By	integrating	the	PARTNER	model	
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approach	into	their	practice,	Kiana’s	healthcare	providers	are	able	to	meet	Kiana	where	she	is,	identify	her	strengths,	and	help	her	develop	an	early	attachment	bond	with	her	baby	by	meeting	her	where	she	is	and	providing	her	with	person-centered,	unbiased,	ethical	medical	care.		
P:	PERSON-CENTERED	The	first	element	of	the	PARTNER	model	is	person-centered.	A	person-centered	approach	is	characterized	by	the	establishment	of	equal	partnership	between	the	provider	and	the	patient	that	is	rooted	in	genuine	empathy	for	individually	lived	experiences.	Equal	partnership	is	the	foundation	of	the	person-centered	approach.	It	requires	providers	to	view	the	patient	as	an	individual	person	with	individual	needs,	leaving	behind	the	one-size-fits-all	mentality.	This	approach	is	vital	to	this	practice	model,	as	it	supports	the	overarching	goal	to	educate,	destigmatize,	and	foster	attachment	as	equal	partners	in	planning	rather	than	from	an	imbalanced	power	approach.	The	provider	and	patient	still	have	their	unique	roles	within	the	relationship,	but	it	is	more	collaborative	in	nature	than	a	traditional	directive	healthcare	approach.	When	working	from	this	framework,	providers	act	as	guides	or	coaches	in	informed	healthcare	decision-making.	This	also	requires	providers	to	acknowledge	the	power	dynamics	that	exist	within	the	patient/provider	relationship,	which	can	often	act	as	barriers	to	developing	this	equal	partnership.	The	benefits	of	creating	this	partnership	can	also	surpass	pregnancy,	as	it	can	open	an	ongoing	doorway	to	developing	and	maintaining	a	safe,	comfortable	relationship	with	health	care	systems	in	general.		Person-centered	care	also	requires	providers	to	respect	and	appreciate	the	patient’s	world,	free	from	judgment	or	stigmatization.	The	empathy	involved	in	person-centered	
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care	goes	beyond	understanding	feelings;	it	requires	a	capacity	for	deeper	understanding	and	acceptance	of	the	patient’s	lived	experiences	from	the	patient’s	individual	life	paradigm.	Through	this	approach,	providers	can	capture	a	patient’s	true	narrative	by	allowing	the	patient	to	guide	and	process	the	narrative	themselves.	It	is	a	holistic	approach	that	requires	providers	to	meet	the	patient’s	needs	in	a	way	that	is	applicable	to	the	patient’s	uniquely	lived	experiences.		
CASE	STUDY	VIGNETTE	
Kiana	was	brought	to	the	hospital	after	overdosing	on	heroin.	She	is	laying	on	a	
stretcher	in	an	emergency	department	room,	feeling	ashamed,	embarrassed,	and	
completely	overwhelmed.	She	has	just	been	told	that	she	is	pregnant,	approximately	12	
weeks’	gestation.	Per	hospital	protocol,	Kiana	is	admitted	to	the	maternal/fetal	
medicine	unit	for	withdrawal	monitoring	and	treatment,	which	involves	medication-
assisted	treatment	initiation.	Allison,	a	licensed	clinical	social	worker,	has	been	
consulted	to	meet	with	Kiana	and	complete	an	initial	assessment	using	the	PARTNER	
model	to	guide	her	approach.	
Allison	knocks	on	the	door,	asking	permission	to	enter	the	room	and	sit	in	the	
open	chair	next	to	Kiana’s	stretcher.	Allison	introduces	herself	and	reviews	her	role	as	
the	perinatal	clinic	social	worker.	Allison	explains	to	Kiana	that	she	is	here	to	meet	
with	her,	provide	support,	and	talk	through	some	questions	to	determine	how	she	can	
be	the	most	helpful.	Allison	explains	that	she	is	going	to	ask	Kiana	several	questions.	
“Kiana,	if	at	any	point	you	feel	overwhelmed	or	uncomfortable,	just	let	me	know.	I	
know	you’ve	had	a	really	tough	day,	so	we	will	move	at	whatever	pace	feels	the	most	
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comfortable	for	you.	We	can	take	a	break	or	stop	at	any	time.	Does	this	sound	okay	
with	you?”	
At	this	point	in	the	interaction,	Kiana	feels	anxious	and	ashamed.	However,	
Allison’s	empathic	understanding	approach	helps	to	put	her	at	ease.	Allison	is	using	a	
person-centered	approach	to	engage	Kiana	and	lay	the	groundwork	for	the	
development	of	an	equal	partnership	between	Kiana	and	her	healthcare	providers.	She	
is	showing	respect	for	Kiana’s	physical	and	mental	space	by	asking	for	permission	to	
enter	the	room	and	putting	the	control	of	the	assessment	pace	in	Kiana’s	hands.	
	 Throughout	the	assessment,	Kiana	reveals	clinically	significant	aspects	of	her	
life	that	have	been	empirically	identified	as	risk	factors	for	opioid	dependency.	Allison	
is	engaged	in	active	listening,	providing	empathic	validation	while	assessing	for	
Kiana’s	needs.	Allison	also	discusses	pregnancy	options	(parenting,	adoption,	and	
termination)	without	making	any	assumptions,	practicing	from	a	collaborative,	rather	
than	authoritative,	approach.	Kiana	shares	that	she	would	like	to	move	forward	with	
the	pregnancy	and	parent	her	baby	but	does	not	know	where	to	start.	
Allison	introduces	the	opportunity	to	help	connect	Kiana	to	an	ob/gyn	for	
prenatal	care	and	medication-assisted	treatment	programs,	discussing	all	of	the	
options	with	her.	Kiana	expresses	interest	in	initiating	this	type	of	treatment.	Allison	
asks	Kiana,	“We’ve	talked	about	a	few	different	programs.	Based	on	what	you’ve	told	
me	about	you,	I	think	the	buprenorphine	clinic	that	specializes	in	perinatal	health	
would	be	great	for	you.	What	do	you	think?”	Again,	by	taking	this	approach,	Allison	
practicing	from	a	collaborative,	rather	than	authoritative,	approach.	She	is	creating	
an	equal	partnership	with	Kiana	and	is	giving	her	autonomy	in	evaluating	her	
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healthcare	decisions.	Kiana	agrees	to	starting	buprenorphine	medication-assisted	
treatment	management	with	the	perinatal	addiction	clinic.	Allison	provides	a	warm	
handoff	to	both	the	perinatal	addiction	clinic	and	outpatient	ob/gyn	clinic	teams.		
	
A:	ATTACHMENT-INFORMED	The	second	element	of	the	PARTNER	model	is	attachment-informed.	An	attachment-
informed	approach	involves	integrating	support,	psychoeducation,	and	engagement	that	fosters	relationship	building	between	providers	and	the	patient,	as	well	as	the	patient	and	the	baby.	The	empirical	research	uncovered	has	revealed	that	incorporating	psychosocial	factors	like	breastfeeding,	bonding,	swaddling,	cuddling,	and	family	involvement	improves	outcomes	for	infants	with	intrauterine	opioid	exposure.	The	literature	also	reveals	that	additional	psychosocial	factors,	like	nurturing,	supportive,	stable	homes	with	social	and	family	protective	factors,	provide	further	improved	short-	and	long-term	physical	and	behavioral	outcomes	for	these	infants	and	their	families.	Each	of	these	factors,	though	individually	beneficial,	are	all	linked	by	an	extremely	significant	common	denominator.	They	are	all	components	of	early	attachment	development.		Although	there	are	several	generalizable	infant	cues	(for	example,	crying	when	hungry),	each	infant	communicates	differently	than	the	other.	Neonatal	abstinence	syndrome	can	play	a	significant	role	in	this	attachment	development	and	the	way	in	which	babies	interact	with	their	attachment	figures.	Symptoms	of	NAS	directly	impact	the	way	in	which	the	baby	eats,	sleeps,	and	cries.	Infants	initially	utilize	crying	as	a	form	of	expression,	but	eventually	crying	becomes	the	infant’s	primary	mode	of	communication	with	the	mother.	This	is	the	infant’s	primary	and	initial	form	of	communication	with	the	mother.	
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The	infant’s	cry	initiates	physiological	responses	within	the	mother	that	induce	breastmilk	production.	A	mother	can	develop	an	incredibly	strong	bond	with	her	child	as	she	learns	to	speak	her	child’s	language.	Eye	contact,	physical	contact,	and	verbal	contact	are	all	key	elements	of	attachment	development	between	the	mother	and	infant.	To	develop	a	strong	attachment	bond,	these	activities	must	be	consistent	and	reliable.	Consistency	is	predictable	and	inherently	safe.	This	is	an	important	consideration	when	working	from	an	attachment-informed	framework	to	foster	partnership	between	the	mother	and	her	baby,	as	well	as	the	mother	and	her	providers.		
CASE	STUDY	VIGNETTE	
Kiana	presents	to	the	ob/gyn	clinic	office	for	her	first	prenatal	care	visit.	Kiana	
looks	around	and	sees	several	other	pregnant	women	in	the	waiting	room.	Kiana	
wonders	to	herself,	“Do	I	even	belong	here?	Do	I	even	deserve	to	be	a	mom?”	Kiana	
timidly	approaches	the	front	desk	to	start	the	check-in	process.	Terrie,	the	ob/gyn	
practice	manager,		greets	her	with	a	warm	smile.		
“Hi	Kiana,	thank	you	so	much	for	coming	to	see	us	today.	How	are	you	feeling?”	
“I’m	okay,	thanks,”	Kiana	responds.	Kiana	still	feels	hesitant	but	notices	a	sense	of	
relief.	“We	have	some	paperwork	for	you	to	fill	out,”	Terrie	says.	“Take	your	time,	no	
rush.	If	you	have	any	questions,	just	let	me	know.	I’m	here	to	help.”	Terrie	
acknowledges	the	imbalanced	power	dynamic	that	exists	between	healthcare	
providers	and	patients.	She	is	engaging	Kiana	from	an	attachment	perspective,	
utilizing	a	nurturing,	supportive	approach.		
After	her	paperwork	is	completed,	Kiana	is	greeted	by	Beth,	one	of	the	ob/gyn	
office	nurses.	Beth	walks	Kiana	back	to	the	patient	room	and	completes	her	vitals.	Beth	
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asks	Kiana	if	she	has	any	questions	or	concerns	that	she	would	like	to	address	during	
her	visit	today.	Kiana	has	more	questions	than	she	can	count,	but	she	quietly	responds,	
“I’m	not	really	sure.”	Beth	recognizes	that	this	is	a	stressful,	intimidating	situation	for	
Kiana.	To	normalize	Kiana’s	feelings,	Beth	responds,	“That’s	okay.	I	don’t	know	any	
new	moms-to-be	who	know	exactly	where	to	start.	There’s	so	much	to	think	about!	
Why	don’t	we	start	with	what	to	expect	for	this	visit?”	Beth	provides	Kiana	with	an	
overview	of	the	first	prenatal	care	visit.	Like	Terrie,	she	is	engaging	Kiana	from	an	
attachment	perspective,	utilizing	a	nurturing,	supportive	approach.		
Shortly	after	Beth	leaves	the	room,	Dr.	Ziegel	knocks	on	the	door,	asks	
permission	to	enter	the	room.	“Hi	Kiana,	it’s	so	nice	to	meet	you.	My	name	is	Dr.	Ziegel,	
but	everyone	calls	me	Jenny,”	she	says.	During	Jenny’s	evaluation	and	assessment,	she	
asks	Kiana	some	questions	about	her	opioid	use	disorder	history	and	the	newly	
initiated	medication-assisted	treatment	management.	Kiana	states	has	been	working	
well	for	her	thus	far,		but	Jenny	notices	Kiana	appears	visibly	upset.	Jenny	asks,	“What’s	
going	through	your	mind,	Kiana?”	Kiana	replies,	“What’s	going	to	happen	to	my	baby?”	
Jenny	takes	the	time	to	answer	all	of	Kiana’s	questions.	Jenny	explains	the	
different	ways	in	which	opiates	and	buprenorphine	interact	with	the	baby	in	utero,	
reassuring	Kiana	that	the	baby	is	safer	with	the	medication	assisted	treatment.	Jenny	
provides	education	on	neonatal	abstinence	syndrome,	explaining	the	diagnosis	and	
treatment	process.	Jenny	also	provides	education	on	mandated	reporting	laws,	
explaining	that	the	hospital	is	legally	required	to	notify	child	protective	services	of	any	
unprescribed	opioid	use	during	pregnancy.	Jenny	also	emphasizes	the	impactful	role	of	
maternal	engagement	and	attachment	bonding	activities	in	the	NAS	treatment	
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process.	By	doing	this,	Jenny	is	laying	the	groundwork	for	early	attachment	bond	
development.	Jenny	is	thoroughly	explaining	all	aspects	of	the	perinatal	opioid	
dependency,	but	discusses	these	sensitive	topics	using	supportive,	unthreatening,	
approach.	The	goal	is	to	foster	inclusion	and	partnership	rather	than	fear	and	
disconnection.	Jenny	is	letting	Kiana	know	that	she	is	not	only	deserving	of	being	a	
mother,	but	she	is	needed	and	an	important	part	of	the	baby’s	treatment	team.		
R:	RISK	REDUCTION	The	third	element	of	the	PARTNER	model	is	risk	reduction.	Engaging	in	a	risk	reduction	approach	involves	working	together,	with	the	patient,	toward	the	establishment	of	safety	and	improvements	rather	than	perfection.	Risk	reduction	involves	realistic,	sustainable	goal	setting	with	realistic,	individualized	expectations,	as	well	as	identifying	and	mitigating	barriers	to	achieving	these	goals.	Goal-setting	can	include,	and	is	not	limited	to,	discussions	surrounding	treatment,	parenting,	child	protective	services.	These	goals	can,	and	likely	will,	evolve	throughout	the	pregnancy	and	postpartum	periods.	By	guiding	the	patient	through	the	thought	process	of	goal-setting,	providers	can	help	set	the	patient	up	for	successful	outcomes.	A	patient’s	goals	should	be	augmented	by	psychoeducation	to	ensure	informed	decision-making.	This	is	especially	important	when	discussing	harm	reducing	practices	in	blood	borne	infectious	diseases	and	overdose	prevention.		Again,	risk	reduction	works	toward	establishing	safety	and	improvements	rather	than	perfection.	This	is	important	for	the	provider	to	consider	as	well,	not	just	the	patient.	Research	shows	that	providers	can	expect	some	degree	of	noncompliance	and	inconsistency	in	care	planning	with	people	who	suffer	from	addiction	(Tkacz,	Severt,	Cacciola,	&	Ruetsch,	2011).	Providers	should	respect,	acknowledge,	and	appreciate	any	
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preexisting	and	ongoing	challenges	of	a	patient’s	lived	experiences.	Providers	should	also	respect	patient’s	right	to	disclose	sensitive	information	and	accept	that	patient	may	not	always	be	forthcoming,	especially	given	the	context	of	the	heavy	stigma	surrounding	pregnancy	and	addiction.	Maintaining	realistic	expectations	supports	the	person-centered	approach	and	reduces	occurrence	of	stigma,	as	it	recognizes	and	respects	each	individual	patient’s	abilities,	strengths,	and	needs.	A	patient’s	care	planning	noncompliance	is	not	indicative	of	flawed	character	or	moral	failing	and	should	be	approached	accordingly.			Identifying	and	mitigating	barriers	to	care	is	an	essential	component	of	this	process,	as	barriers	to	care	often	contribute	to	health	care	noncompliance.	Barriers	to	care,	such	as	lack	of	transportation,	medical	insurance,	housing,	and	other	resources	are	significantly	more	likely	to	be	lost	to	care	than	those	patients	who	have	their	basic	needs	met.	In	cases	where	barriers	do	not	have	an	identifiable	or	viable	solution,	providers	should	consider	referring	out	to	external	agencies	for	ongoing	case	management	support.	It	may	not	be	possible	to	mitigate	all	barriers	to	care,	but	again,	the	aim	should	be	toward	improvement,	not	perfection.		
CASE	STUDY	VIGNETTE	
Kiana	returns	to	the	ob/gyn	office	next	prenatal	appointment.	Kiana	is	greeted	
by	her	doctor,	Jenny,	with	a	warm	smile.	“It’s	so	great	to	see	you	again,	Kiana.	Thank	
you	for	coming	to	see	us	today.”	After	her	prenatal	exam	and	labs	are	completed,	
Kiana	anxiously	shares	with	Jenny	that	she	experienced	a	brief	relapse	last	week.	
Kiana	is	terrified	and	embarrassed	to	admit	this,	as	she	does	not	want	anyone	to	think	
she	does	not	love	her	baby.	However,		the	consistently	nonjudgmental	engagement	
Kiana	experiences	with	her	healthcare	team	helps	her	feel	more	comfortable	sharing	
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this.	Jenny	acknowledges	and	commends	Kiana	for	her	bravery	in	sharing	this	
information.	
	Jenny	is	well-versed	in	opioid	use	disorders	and	understands	that	relapse	is	an	
anticipated,	commonly	experienced	aspect	of	the	recovery	process.	Jenny	approaches	
her	practice	with	an	aim	for	improvement,	not	perfection.	Jenny	also	practices	from	a	
disease-model	approach,	making	sure	to	emphasize	to	Kiana	that	this	relapse	is	part	of	
the	process,	not	a	moral	failing	or	character	flaw.		
Jenny	provides	Kiana	with	some	brief	supportive	counseling,	motivational	
interviewing	techniques,	and	psychoeducation	on	the	opioid	addiction	recovery	
process.	Jenny	also	reviews	some	additional	risk	reduction	information,	including	
education	about	needle	sharing	and	needle	exchanges.	Her	goal	is	to	keep	Kiana	and	
her	baby	as	safe	as	possible.	Jenny	also	asks	some	questions	to	assess	for	access	to	basic	
needs	and	barriers	to	care,	uncovering	that	Kiana	is	having	a	hard	time	navigating	
WIC	program	benefits.	Jenny	offers	to	send	a	referral	to	local	non-profit	agency	that	
provides	case	management	supports	to	pregnant	women	with	opioid	use	disorders,	
which	Kiana	accepts.		
	
T:	TRAUMA-INFORMED		 The	fourth	element	of	the	PARTNER	model	is	trauma-informed.	Practicing	from	a	trauma-informed	approach	involves	the	establishment	safety	between	the	patient	and	the	provider	through	connection	and	authenticity.	Safety	is	the	cornerstone	of	attachment	development.	Creating	a	sense	of	basic	safety	is	necessary	for	patients	to	feel	comfortable	with	engaging	with	their	healthcare	providers.	Successfully	establishing	safety	is	heavily	
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dependent	on	the	patient’s	individual	trauma	history	and	attachment	style,	but	providers	can	continuously	work	toward	creating	physical	and	emotional	safety	within	the	patient/provider	relationship	(Sanders	&	Hall,	2018).	Patients	need	to	feel	physically	safe	within	the	immediate	space	between	themselves	and	the	providers.	Patients	also	need	to	feel	emotionally	safe	within	the	patient/provider	relationship.	Emotional	safety	can	be	established	through	the	use	of	clear,	calm	communication,	as	well	as	mindfulness	of	verbal	and	non-verbal	language.	Patients	need	to	feel	safe	simply	being	themselves.		To	develop	this	kind	of	close	relationship	with	a	patient,	it	is	ethically	imperative	that	the	relationship	is	authentic,	genuine,	and	trustworthy.	Providers	should	take	the	time	to	learn	their	patient’s	preferences,	strengths,	needs,	and	values	and	integrate	these	factors	into	care	planning.	This	approach	also	requires	implementation	of	cultural	considerations,	which	aids	in	solidifying	the	respect	for	individual	life	and	identity.	Within	the	context	of	this	authentic	relationship,	patients	learn	to	trust	their	providers,	which	results	in	stronger	engagement	and	relationship-building.	Establishing	an	authentic	relationship	promotes	transparency,	respect,	and	humane	care.	
CASE	STUDY	VIGNETTE	
Kiana	presents	to	the	hospital	for	her	scheduled	induction	of	labor.	Kiana	first	
meets	with	her	nurse,	Kerry,	who	notices	that	Kiana	is	visibly	nervous.	Kiana	is	looking	
down	at	her	hands,	fidgeting,	and	avoiding	eye	contact.	Kerry	greets	Kiana	with	
warmth,	kindness,	and	reassurance.	Kerry	understands	the	importance	of	building	an	
authentic,	genuine	rapport	with	Kiana	to	foster	trust	and	safety.		
Kerry	introduces	herself	and	utilizes	light,	appropriate	humor	to	help	put	Kiana	
at	ease.	“The	labor	induction	process	can	take	several	hours	sometimes.	If	you	get	
 75 
bored	and	I’m	not	in	another	patient’s	room,	I’d	be	happy	to	provide	you	with	a	special	
‘Karaoke	Kerry’	performance.”	Another	nurse,	Bobbi,	chimes	in	and	says,	“Trust	me,	
you	don’t	want	to	hear	any	of	that	–	‘Karaoke	Kerry’	is	not	as	talented	as	she	thinks	she	
is.”	Kerry	and	Kiana	share	a	laugh	together,	which	helps	Kiana	feel	more	comfortable	
and	connected	to	her	unfamiliar	surroundings.		
	Kerry	begins	with	the	routine	intake	evaluation,	starting	with	less	stressful	
screening	questions,	like	smoking	cigarettes.	“Kiana,	do	you	smoke	cigarettes	or	use	
any	tobacco	products?	If	so,	how	often?”	Kiana	quietly	responds	that	she	does	smoke	
cigarettes,	about	four	to	five	times	per	week.	Kerry	responds	by	offering	to	get	Kiana	a	
nicotine	patch	to	use	during	her	admission,	which	Kiana	declines	for	now.	Kerry	tells	
Kiana,	“If	at	any	point	you	feel	like	you	need	one,	just	let	us	know.	The	labor	induction	
process	can	be	stressful	and	take	a	long	time.	I’m	here	to	support	you	through	this	
process,	so	please	do	not	hesitate	to	use	the	call	bell	to	let	me	know	if	you	change	your	
mind.	Kerry	is	aware	that	hospitalizations	come	with	several	stressful	stimuli	that	can	
contribute	to	traumatic	experiences.	Kerry	reminds	Kiana	throughout	her	labor	
induction,	“Whatever	you	need,	I’m	here	for	you.”	
Kerry	moves	forward	with	the	intake	process	and	reviews	Kiana’s	medication-
assisted	treatment	management.	Kiana	still	feels	a	bit	nervous,	but	Kerry’s	warmth	
and	humanistic	approach	to	care	helps	to	put	Kiana	at	ease.	Kerry	answers	all	of	
Kiana’s	questions	with	transparency.		This	is	especially	important	in	regard	to	
toxicology	screenings,	NAS	monitoring,	and	child	welfare	involvement.	Kerry	is	also	
sure	to	ask	if	there	will	be	any	visitors	who	are	unaware	of	Kiana’s	recovery.	Kiana	
explains	that	her	mother	and	boyfriend	are	aware,	but	her	two	younger	sisters	are	not.	
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She	asks	that	no	one	mentions	this	in	front	of	them.	Kerry	assures	Kiana	that	this	
information	will	be	noted	in	her	chart	and	included	in	all	handoffs,	further	fostering	
safety	and	respect.		
	
N:	NEUTRALITY	
	 The	fifth	element	of	the	PARTNER	model	is	neutrality.	Neutrality	is	characterized	by	fully	objective,	nonjudgmental	care	and	is	maintained	through	self-awareness	and	self-evaluation.	All	patients	have	the	right	to	objective	healthcare	that	is	free	from	judgment,	prejudice,	and	bias.	This	is	especially	important	for	providers	working	with	pregnant	and	postpartum	women	with	opioid	use	disorders,	as	the	stigma	they	experience	is	amplified.	This	marginalized	group	of	postpartum	women	endure	all	the	standard	postpartum	challenges	while	simultaneously	drowning	in	disapproval	and	judgment	that	is	so	brazenly	conveyed	by	others,	especially	hospital	staff	members.	There	is	concrete,	measurable	weight	and	influence	in	the	way	in	which	a	patient	believes	he	or	she	is	perceived	by	a	person	in	an	authoritative	position.	Providers	are	inherently	viewed	as	powerful.	Internalized	feelings	of	guilt	and	shame	are	amplified	by	the	judgment	and	stigma	imparted	on	them	by	providers.	Providers	have	an	ethical	responsibility	to	develop	and	maintain	self-awareness	to	mitigate	implicit	bias	and	countertransference.	When	faced	with	any	internal	challenges	that	could	compromise	the	integrity	and	neutrality	of	their	work,	providers	should	seek	consultation.		
CASE	STUDY	VIGNETTE	
After	several	hours	of	labor	induction,	Kiana	gives	birth	to	a	healthy	baby	boy	
named	William.	William	was	immediately	placed	on	Kiana’s	chest	,	initiating	early	
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attachment	bonds	straightaway	from	birth	by	promoting	skin-to-skin	Kangaroo	care.	
Kiana’s	nurse,	Bobbi,	taught	her		how	to	swaddle	the	baby	and	provided	her	with	
breastfeeding	education	and	support.	Kiana	and	William	are	being	given	objective,	
unbiased	treatment	that	all	mothers	and	babies	deserve.		
Kiana’s	providers	are	mindful	of	their	language	choice.	During	morning	rounds,	
the	team	identifies	that	Kiana	is	on	medication-assisted	treatment,	which	requires	an	
extended	admission	for	William	to	monitor	for	NAS	symptoms.	They	never	refer	to	
Kiana	as	a	“drug	mom”	or	“Subutex	mom.”	They	never	refer	to	William	as	a	“drug	
baby”	or	a	“Subutex	baby.”	The	team	prioritizes	destigmatizing,	person-first	language.	
The	team	consistently	respects	Kiana’s	wishes	in	regard	to	who	can	be	present	during	
sensitive	discussions.		
The	postpartum	hospital	social	worker,	Danielle,	stops	by	Kiana’s	room	to	
introduce	herself	and	congratulate	Kiana	on	the	birth	of	her	baby.	“Hi	Kiana,	my	name	
is	Danielle.	It’s	so	nice	to	finally	meet	you.	I’m	one	of	the	postpartum	social	workers	
that	works	with	Allison.	I’m	not	sure	if	you	remember	her;	you	met	her	a	few	months	
ago.”	Kiana	remembers	Allison,	the	social	worker	who	helped	her	get	connected	to	the	
perinatal	addiction	medicine	and	ob/gyn	clinics.	Kiana	remembers	Allison’s	kind,	
nonjudgmental	demeanor.	Through	the	use	of	warm	handoffs,	Kiana’s	provider	team	is	
able	to	preserve	and	build	upon	these	connections	and	relationships.	
	Danielle	continues,	“Allison	is	off	until	Wednesday,	but	she	let	me	know	you	
were	scheduled	for	induction	this	week.	She’s	so	bummed	about	missing	you,	but	she	
will	be	back	before	you	leave.	I	don’t	want	to	interrupt	your	bonding	time	with	William	
now,	so	I	will	come	back	tomorrow.	Is	there	any	particular	time	that	you’d	prefer?”	By	
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integrating	these	aspects	of	neutrality	and	connection	into	her	care,	Kiana’s	
healthcare	providers	have	created	a	safe	space	where	she	can	truly	enjoy	her	first	
moments	of	motherhood	with	humanity,	dignity,	and	respect,	free	from	bias	and	
judgment.		
E:	EMPOWERMENT	
	 The	sixth	element	of	the	PARTNER	model	is	empowerment.	Empowerment	is	characterized	by	the	promotion	of	self-worth	and	autonomy.	To	truly	empower	patients,	providers	first	need	to	recognize	and	break	down	influences	of	stigma	to	promote	worthiness	of	self.	The	stigma	of	addiction	as	a	moral	failing	can	permeate	into	the	patient’s	belief	in	their	deservingness	of	motherhood.	At	the	most	basic	level	of	humanity,	the	patient	still	has	the	right	to	be	a	person.		
	 The	way	in	which	providers	work	toward	creating	a	sense	of	empowerment	in	patients	needs	to	be	individualized	and	person-centered,	especially	in	the	context	of	perinatal	opioid	use	disorders.	In	order	for	patients	to	experience	a	sense	of	empowerment,	providers	should	provide	proactive	psychoeducation	and	tools	to	promote	autonomous	and	informed	decision-making.	This	is	especially	important	in	the	transparency	mandated	reporting	laws	and	policies,	as	well	as	potential	child	welfare	outcomes.	The	education,	support,	and	encouragement	needs	to	be	applicable	and	appropriate	for	each	individual	patient’s	situation	and	circumstances.	For	example,	the	ability	to	safely	breastfeed	the	baby	may	not	be	possible	for	some	patients	depending	on	active	opioid	use	and/or	contraindicated	medications.	In	this	type	of	situation,	providers	should	identify	other	ways	to	empower	the	patient	without	shaming	or	diminishing	self-worth.	
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CASE	STUDY	VIGNETTE	
The	following	day,	Danielle	returns	to	meet	with	Kiana.	Danielle	is	aware	that	
although	she	briefly	met	with	Kiana	yesterday,	she	needs	to	continue	to	establish	
rapport	with	Kiana.	Danielle	engages	with	Kiana,	giving	Kiana	the	opportunity	to	
process	her	feelings	about	her	pregnancy,	labor,	and	first	childbirth	experience.	
Danielle	connects	with	Kiana	over	the	baby’s	name,	sharing	that	her	best	friend’s	name	
is	William.		
Danielle’s	assessment	covers	several	areas,	including	evaluating	for	access	to	
basic	needs,	infant	preparedness,	social	supports,	and	postpartum/newborn	
psychoeducation.	Danielle	also	reviews	clinical	assessment	information,	including	
mental	health	history,	postpartum	depression	screening,	intimate	partner	violence,	
substance	use	history,	and	mandated	reporting	laws.	Kiana	is	already	aware	of	
mandated	reporting	laws	and	required	child	protective	services	report.	She	remembers	
having	this	discussion	with	Jenny	during	one	of	her	prenatal	care	visits.		
Kiana	shares	with	Danielle	that	she	feels	well-prepared	for	this	process,	but	she	
is	still	afraid.	Kiana	discloses	feelings	of	shame	and	guilt.	She	reveals	to	Danielle,	“I	feel	
like	I’m	a	bad	person	and	a	bad	mom.	William	deserves	better	than	me.	It’s	my	fault	
that	he	has	to	go	through	withdrawal.	I	know	what	that	feels	like,	and	I	can’t	believe	
my	mistakes	are	causing	my	baby	to	feel	that	way.	I	don’t	want	anyone	to	think	I	don’t	
love	my	baby.”		
Danielle	recognizes	Kiana’s	addiction	and	child	protective	service	involvement	
is	not	new	information,	but	this	information		has	new	context	now	that	the	baby	has	
been	born.	Danielle	gives	Kiana	the	space	to	talk	through	and	process	these	feelings,	
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while	utilizing	supportive	counseling	and	cognitive-behavioral	techniques	to	work	
toward	mitigating	the	cognitive	distortions.	Danielle	works	together	with	Kiana	to	
reframe	her	thoughts,	highlighting	Kiana’s	growth,	protective	factors,	and	resilience.		
Most	importantly,	Danielle	reassures	Kiana	that	she	is	an	integral	part	of	
William’s	care	team,	reminding	her	that	maternal	engagement	and	early	attachment	
bond	development	is	scientifically	shown	to	positively	impact	NAS	treatment	outcomes	
and	early	childhood	development.	By	doing	this,	Danielle	is	working	toward	restoring	
Kiana’s	self-worth	and	empowering	her	to	be	an	active	participant	in	William’s	care.	
	
R:	REINFORCEMENT	The	seventh	and	final	element	of	the	PARTNER	model	is	reinforcement.	Reinforcement	is	characterized	by	repetition	and	consistency.	Patients	regularly	do	not	retain	most	of	the	information	they	receive	from	their	healthcare	providers.	This	is	especially	evident	in	the	setting	of	stressful	stimuli,	which	directly	impacts	memory	function.	Stressful	stimuli	can	also	activate	maladaptive	self-defense	mechanisms,	self-destructive	cognitive	distortions,	and	denial.	When	faced	with	unpleasant	circumstances,	patients	may	also	subconsciously	pick	certain	pieces	of	information	to	remember	or	ignore	to	appease	the	ego.	Providers	should	be	willing	to	review	education	and	information	in	various	formats	to	meet	their	patient’s	needs.	The	process	of	repetition	should	be	approached	with	patience,	anticipation,	and	empathy.				 Providers	should	also	be	providing	consistent	information	with	a	united	approach	to	care.	This	practice	is	integral	to	this	model,	as	it	fosters	trust	and	reduces	ambiguity.	Consistency	is	especially	important	when	discussing	sensitive	topics	including	infant	
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withdrawal	monitoring	protocol,	NAS,	and	child	protective	service	involvement.		Providing	consistent	information	is	not	only	ethically	imperative,	but	it	aids	in	reducing	ambiguity	for	the	patient.	Consistency	can	be	cultivated	through	wraparound	support	approaches	and	warm	handoffs	to	ensure	continuity	of	care.	
	
CASE	STUDY	VIGNETTE	
	 It	is	the	discharge	day	for	Kiana,	but	William’s	admission	continues	for	NAS	
monitoring.	Kiana	knows	this	day	was	going	to	come,	but	it	still	doesn’t	feel	real.	After	
Kiana	is	formally	discharged	from	the	hospital,	William	is	transferred	to	the	nursery,	
where	he	will	remain	for	at	least	the	next	two	days.	William	may	need	to	stay	for	
longer,	depending	on	his	withdrawal	symptoms.	Kiana	returns	to	her	mother’s	home	to	
unpack	her	bags	and	take	a	shower	but	returns	to	the	hospital	shortly	afterward	to	
stay	by	William’s	side.	When	Kiana	arrives	at	the	nursery,	she	feels	overcome	with	
doubt,	asking	herself,	“Do	I	even	belong	here?	Do	I	even	deserve	to	be	a	mom?”	
	 Moments	after	entering	the	nursery,	Kiana	is	greeted	by	William’s	nurse,	Steph.	
“Hi	Kiana,	my	name	is	Steph	and	I’ll	be	taking	care	of	William	with	you	today.	You’re	
just	in	time	for	rounds!	This	is	Robert,	the	attending	pediatrician.”	Robert	turns	to	
Kiana,	extending	his	arm	and	gesturing	to	Kiana	to	come	join	the	discussion.	Steph	and	
Robert	are	aware	of	how	intimidating	this	environment	can	feel.	They	know	Kiana	has	
been	educated	on	the	benefits	of		early	attachment	bonding,	but	they	are	reinforcing	
this	message	to	engage	her	as	an	active,	important	member	of	the	baby’s	treatment	
team.		
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	 Steph,	Robert,	and	other	members	of	the	team	include	Kiana	in	the	care	
planning	discussion	during	rounds.	They	review	William’s	newborn	delivery	notes	and	
his	treatment	plan,	consistently	using	person-first,	destigmatizing	language.	Robert	
reviews	NAS	scoring	protocol	with	Kiana,	showing	her	the	Modified	Finnegan	NAS	
Scoring	Sheet	as	they	discuss	William’s	scores	over	the	past	24	hours.	Robert	knows	
Kiana	has	been	educated	on	the	NAS	scoring	process.	However,	he	also	understands	
the	benefit	of	repetition,	especially	considering	the	significant	stimuli	exposure	Kiana	
has	experienced	over	the	past	few	days.		
Steph	reviews	Kiana’s	breastfeeding	plan,	pausing	every	so	often	to	create	the	
opportunity	for	equal	partnership	discussion	and	questions.	Feeling	comfortable	as	a	
member	of	the	care	team,	Kiana	asks,	“Is	it	definitely	safe	for	me	to	breastfeed	with	the	
Subutex?”	Steph	knows	Kiana	has	been	educated	on	the	efficacy	and	safety	of	
breastfeeding	while	taking	Subutex,	but	she	also	recognizes	the	importance	of	
reinforcement	and	conveying	consistent	messages.	Steph	provides	her	with	
reassurance,	validation,	and	offers	to	bring	in	one	of	the	lactation	consultants	for	
ongoing	breastfeeding	support.		
At	the	end	of	rounds,	the	team	asks	Kiana	if	she	has	any	other	questions.	Kiana	
replies,	“Is	it	okay	to	hold	him?”		Robert	picks	William	up	out	of	his	hospital	crib	and	
hands	him	to	Kiana	with	a	warm	smile.	He	says	to	her,	“William	is	such	a	lucky	boy	to	
have	you	as	his	mom.”	
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CHAPTER	VI:	CONCLUSION	
CONCLUDING	STATEMENT		 The	need	for	an	evidence-informed	approach	like	the	PARTNER	model	is	evident.	The	PARTNER	model	is	the	first	research-informed,	systematically	developed	practice	model	designed	to	specifically	address	the	unique	needs	of	mothers	and	babies	impacted	by	the	perinatal	opioid	epidemic.	It	is	intended	to	be	as	comprehensive	as	possible,	but	it	is	not	a	finite,	independent	solution	this	macro-level	problem.	There	are	countless	potential	combinations	of	demographics,	risk	factors,	and	comorbidities	that	could	impact	the	way	in	which	the	PARTNER	model	is	integrated	into	practice.		Future	recommendations	include	the	development	of	a	structured	curriculum	to	educate	providers	on	each	of	the	elements	of	the	PARTNER	model	and	how	to	effectively	integrate	them	into	clinical	practice.	Future	recommendations	also	include	both	short-term	and	longitudinal	evaluation	of	the	PARTNER	model,	with	possible	areas	of	focus	including	changes	in	mother/infant	bonding,	maternal	engagement	in	care,	NAS	treatment	outcomes,	and	a	length	of	stay	cost/benefit	analysis.			 Though	the	efficacy	of	the	PARTNER	model	has	not	yet	been	empirically	measured,	it	is	a	clinically	valuable	and	innovative	approach	that	fills	a	deep,	destructive	gap	in	current	practice	in	working	with	mothers	and	infants	impacted	by	perinatal	opioid	use	disorders.	The	value	and	impact	of	early	attachment	bonding	cannot	be	underestimated.	Early	attachment	bonding	creates	a	pathway	for	the	way	in	which	individuals	engage	in	human	relationships	across	the	lifespan.	Continuing	the	current	practices	of	alienating,	ostracizing,	and	stigmatizing	pregnant	and	postpartum	women	with	opioid	use	disorders	will	only	perpetuate	this	cycle	of	separation,	disconnection,	and	fear.		
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By	integrating	the	PARTNER	model	into	the	standard	of	care,	healthcare	providers	can	help	mothers	and	infants,	like	Kiana	and	William,	by	working	toward	breaking	down	the	socially-created	barriers	of	stigma	and	fear	that	interfere	with	early	attachment	bonding,	an	essential	aspect	of	human	development	that	deserves	to	be	regarded	as	a	basic	human	right.				 				
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